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Abstract 
Background: Limited “real-world” evidence exists supporting insulin pump therapy (IPT) 
benefits in adults with type 1 diabetes mellitus (T1DM).  
Methods: A retrospective matched cohort study compared the change in glycated 
hemoglobin (A1C) and incidence of adverse events before and after IPT start in adults 
with T1DM at St. Joseph’s Healthcare in London, Ontario started on IPT between 
September 2008 – August 2011 to those of a matched control cohort. Paired t-tests, 
McNemar’s test and negative binomial regression were used.  
Results: 174 matched pairs were included. At 1 year, glycaemic control significantly 
improved in IPT users but not in controls—the mean paired difference in A1C change 
was -0.3% (p=0.041, n=133 pairs)—and severe hypoglycaemia was lower in IPT than 
controls (p=0.016). 
Conclusions: Provincially-funded IPT in adults with T1DM was associated with clinically 
significant improvement in glycaemic control and severe hypoglycaemia, providing “real-
world” evidence supporting continued IPT funding in adults with T1DM. 
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Chapter 1: Introduction 
1.1 Overview and Statement of the Problem 
Diabetes mellitus is a common metabolic disorder characterized by chronic 
hyperglycaemia, and can be broadly classified by etiology into Type 1 and Type 2. Type 1 
diabetes mellitus (T1DM) is a result of insulin deficiency due to pancreatic beta-cell 
destruction. It is most commonly due to an autoimmune process and requires daily 
insulin treatment.  In 2013, it was estimated that ~ 381 million people worldwide, 
including ~2.6 million people in Canada, have diabetes mellitus, of which 5-15% have 
T1DM.1  The prevalence of T1DM, and of diabetes mellitus overall, is increasing.1   
Insulin is the mainstay of treatment in T1DM, and the goal of insulin treatment is to 
achieve blood glucose levels as close to normal levels as safely as possible. Strict 
glycaemic control has been shown to decrease microvascular and neuropathic 
complications, and also potentially reduce macrovascular complications, in patients with 
T1DM. However, the benefits of strict glycaemic control must be balanced against the 
risk of hypoglycaemia. 
Intensive insulin treatment is the standard of care in T1DM, and it can be delivered 
through use of insulin pump therapy (IPT) or a multiple daily insulin injection (MDI) 
regimen.2 Insulin pump therapy is the use of a small, portable external pump attached to 
a subcutaneous catheter to deliver a continuous basal infusion of insulin throughout the 
day, as well as intermittent bolus insulin doses for meals. An MDI (or “basal-bolus”) 
regimen is the use of injections of long- or intermediate-acting insulin once or twice 
daily combined with injections of rapid- or short-acting insulin with each meal.  
Meta-analyses of randomized controlled trials comparing IPT to MDI regimens in 
different patient populations have shown that IPT improves glycaemic control. 3-11 
However, the evidence is less clear regarding the benefit of IPT in improving other 
clinically relevant outcomes, such as severe hypoglycaemic events and quality of life, 
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and it is not known whether IPT ultimately reduces the risk of glycaemic-responsive 
complications.  Further, the relevance of these results to the “real-world” is not clear.   
A major barrier to IPT is the financial burden associated with its use—the average price 
of an insulin pump is ~$7,000.00 CAD, and the average cost of pump-associated supplies 
is ~$250.00 CAD per month,12 which may be prohibitive to those without access to 
private insurance coverage. In September 2008, the Ontario Ministry of Health and Long 
Term Care (MOHLTC) began funding of IPT for eligible adults with T1DM through the 
Assistive Devices Program (ADP), and, until recently, Ontario was the only province in 
Canada to provide funding for IPT for adults.   
As a tertiary care referral centre for Southwestern Ontario, St. Joseph’s Health Care 
(SJHC), London provides a regional resource for care of T1DM. Patients with T1DM are 
seen at the Diabetes Clinics at St. Joseph’s Hospital and the Primary Care Diabetes 
Support Program (PCDSP) at the affiliated St. Joseph’s Family Medical Centre. Out of 71 
ADP IPT provider sites for adults in Ontario, SJHC is one of the largest, and is also the 
main ADP IPT provider site within the South West Local Health Integration Network. 
Therefore, our patient population may be considered representative of adults with 
T1DM province-wide, and thus the Diabetes Clinics of SJHC provide a “real-world” 
setting in which the effectiveness of ADP-funded IPT can be closely examined. Since 
2011, the Diabetes Clinics of SJHC have used WebDR, an electronic medical record (EMR) 
system, for routine clinical care.  
To date, the impact of ADP-funded IPT on glycaemic control in adults with T1DM in 
Ontario has not previously been assessed. This study was the first to evaluate this issue. 
In addition, this study was the first use of WebDR for research, and demonstrated its 
utility as a comprehensive researchable database. 
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1.2 Thesis Objectives  
The purpose of this study was to describe the IPT experiences of adult patients with 
T1DM under routine clinical care in the Diabetes Clinics at SJHC in London, Ontario, and 
to assess the clinical impact of IPT funded through the Ontario MOHLTC ADP.  
The main research question was:  
Does ADP-funded IPT improve glycaemic control and reduce adverse outcomes at 1 
year in adults with T1DM followed by the Diabetes Clinics at SJHC? 
To answer this question, the primary objectives were as follows: 
Objective 1: To establish a cohort of adults with T1DM who started on IPT from 
September 1, 2008 – August 31, 2011, using a regional diabetes-specific EMR database, 
for future studies in T1DM. 
Objective 2: To describe the demographic and clinical characteristics of this cohort. 
Objective 3: To compare the glycaemic control of this cohort at 1 year after IPT initiation 
to that of a matched cohort of adults with T1DM not on IPT. 
Objective 4: To compare the frequency of adverse DM-related events in this cohort at 1 
year after IPT initiation, to that of the matched non-IPT cohort. 
The secondary objective of this study was to test the validity of WebDR, the EMR in use 
at the Diabetes Clinics of SJHC, as a researchable database. 
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Chapter 2: Diabetes Mellitus 
2.1 Definition and Types of Diabetes Mellitus 
Diabetes mellitus is a common metabolic disorder characterized by chronic 
hyperglycaemia due to inadequate insulin secretion, inadequate insulin action, or both.2 
Diabetes mellitus can be broadly classified by etiology into Type 1 (T1DM) and Type 2 
(T2DM).  T1DM is most commonly due to autoimmune destruction of the pancreatic 
beta-cells, i.e. Type 1A diabetes (which also includes LADA - latent autoimmune diabetes 
in adults), but occasionally, non-immune-mediated beta-cell destruction can occur, i.e. 
“idiopathic” or Type 1B diabetes.2,13 Both the 1A and 1B subtypes result in insulin 
deficiency and hyperglycaemia which, if left untreated,  causes serious acute and chronic 
consequences.  
 
2.2 Epidemiology of Type 1 Diabetes Mellitus 
In 2013, the worldwide prevalence of all diabetes (both T1DM and T2DM) was estimated 
to be 8.4% or ~381 million people, while the prevalence of all diabetes in Canada was 
10.2% or ~2.6 million people.1 Since T1DM accounts for 5-15% of all cases of diabetes, it 
can be estimated that there are approximately 38.1 million people worldwide and 
260,000 people in Canada with T1DM.  
The worldwide incidence of T1DM has marked geographic variation, with age-adjusted 
incidence rates ranging from 0.1 per 100,000 per year in China and Venezuela to 40.9 
per 100,000 per year in Finland.14 Moreover, the incidence of T1DM is increasing yearly, 
with an overall worldwide increase of 3% per year among children under the age of 
fourteen.1  
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It is difficult to estimate the exact prevalence and incidence of T1DM in adults in 
Ontario, as statistics from the Canadian National Diabetes Surveillance System (NDSS) 
are based upon population-based administrative data which do not distinguish between 
T1DM and T2DM. However, given that T1DM accounts for 5-15% of all cases of diabetes, 
it is assumed that the NDSS statistics reflect this same proportion. Similar to the trend 
worldwide, the most recent NDSS report also showed increasing prevalence and 
incidence of diabetes in Canada from 1998/99 – 2008/09, with Ontario having the third 
highest age-standardized prevalence and second highest age-standardized incidence 
nationwide.15   
 
2.3 Pathogenesis of Type 1 Diabetes Mellitus 
Type 1 diabetes mellitus is characterized by pancreatic beta-cell destruction by either 
immune-mediated (type 1A) or idiopathic/non-immune-mediated processes (type 1B).  
The exact cause of T1DM is not known, though in the case of immune-mediated (type 
1A) diabetes, it is believed that one or more environmental factors may trigger 
development in genetically susceptible people.16  
The major genetic determinant of the risk of T1DM is  contained within the HLA 
genotype, with DR3-DQ2/DR4-DQ8 being the highest risk genotype.17 Other genes 
implicated in the susceptibility to T1DM are the insulin gene18 and the gene for PTPN22, 
a lymphoid-specific phosphatase involved in T-cell receptor signaling.19  
Proposed environmental triggers for the development of T1DM include viral infections, 
such as congenital rubella,20 enterovirus,21 and rotavirus,22 and dietary factors such as 
cow’s milk23 and early exposure to cereal in infancy.24  
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2.4 Management of Type 1 Diabetes Mellitus 
The Canadian Diabetes Association (CDA) recommends that management of T1DM be 
focused around the individual patient, with support from a multi-disciplinary team of 
diabetes experts.2 Important facets of T1DM care include monitoring blood glucose 
levels, physical activity, appropriate nutrition, and insulin administration. The goal of 
T1DM management is the prevention of acute and chronic complications in order to 
reduce morbidity and premature mortality. 
The main laboratory parameter used to monitor glycaemic control in diabetes is the 
glycated hemoglobin (A1C). Hemoglobin is a protein in red blood cells that is essential 
for oxygen transport. Newly formed red blood cells contain hemoglobin that does not 
have any glucose attached—however, as red blood cells are permeable to glucose, 
glucose in the blood irreversibly binds to hemoglobin, forming glycated hemoglobin, at a 
rate dependent on the blood glucose concentration. Given that the average life span of 
a red blood cell is ~120 days, the A1C reflects the mean plasma glucose over the past 3-4 
months. However, it is a weighted average, with blood glucose levels in the preceding 30 
days contributing ~50% of the result, and levels from 90-120 days prior contributing 
~10% of the result. 25 In Canada, A1C is reported in National Glycohemoglobin 
Standardization Program units, which use a percent.2 Therefore, A1C can be expressed 
as a decimal or a percent (i.e. an A1C of 0.070 = 7.0%).  
The Diabetes Control and Complications Trial (DCCT) was a landmark multicentre 
randomized controlled trial in 1,441 patients with T1DM which compared the effect of 
intensive vs. conventional insulin therapy on the development of long-term diabetes-
related complications.26 In the DDCT, the intensive insulin therapy group strived for strict 
glycaemic control, with goal blood glucose levels as close to normal as possible, and a 
target A1C in the normal range, i.e. <0.0605.  However, despite not achieving as tight 
control as targeted (mean A1C attained was 0.072), the intensive insulin therapy group 
experienced a significant reduction in the onset and progression of microvascular and 
neuropathic complications.26 Further epidemiologic analyses of the DCCT results 
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demonstrated a continuous association between A1C and microvascular and 
neuropathic complications, with no obvious threshold below which complications would 
be completely prevented. For example, a 10% reduction in A1C was associated with a 
43% lower risk of retinopathy progression.27 Taken together, these results highlight the 
benefits of tight glycaemic control in patients with T1DM. Based on this evidence, the 
CDA Clinical Practice Guidelines recommend tight glycaemic control, with a target A1C of 
≤ 0.070, in most people with T1DM.2 However, it is also recommended that the target 
A1C level be individualized for patients based on age, duration of T1DM, risk of severe 
hypoglycaemia, and co-morbidities.2  
 
2.5 Complications of Diabetes Mellitus and Its Management  
Uncontrolled hyperglycaemia from suboptimally treated diabetes can result in acute and 
chronic complications. However, over-aggressive treatment of hyperglycaemia can also 
be detrimental as it may cause hypoglycaemia. Thus, the benefits of achieving tight 
glycaemic control to prevent hyperglycaemic-related complications must always be 
weighed against the risks of inducing hypoglycaemia. 
2.5.1 Acute Complications of Uncontrolled Type 1 Diabetes 
In those with T1DM, persistent untreated hyperglycaemia can lead to a hyperglycaemic 
emergency termed diabetic ketoacidosis (DKA). DKA is characterized by hyperglycaemia, 
anion gap metabolic acidosis, and ketone acid production due to insulin deficiency 
(relative or absolute) and excess counter-regulatory hormones. It can be precipitated by 
stressors including omission of insulin, infection, myocardial infarction, trauma, and 
medications.  
The incidence of DKA varies by age and sex but ranges between 4.6 – 8.0 per 1000 
person-years among those with diabetes.28 In Ontario, the rate of hospitalization for 
acute hyperglycaemia (including both DKA and hyperglycaemic hyperosmolar non-
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ketotic state, a related but distinct acute hyperglycaemic condition) in adults ≥ 20 years 
old in 1999 was 458 per 100,000 people.29  There is a wide variation in the range of in-
hospital mortality for patients hospitalized for acute hyperglycaemia—reported 
mortality in Ontario ranged from <1% in those age 20-34 up to ~16% in those age ≥ 75 
years. 29 
In the earlier days of IPT use, several studies observed that IPT was associated with 
higher rates of DKA, most often related to pump infusion system malfunction, 
interrupting the required basal delivery of insulin.30,31 In many cases, rising capillary 
blood glucose values were noted by the patients, but the actual mechanical pump 
problems (i.e. infusion set blockage, pump failure) were missed, leading to rapid loss of 
glycaemic control and the development of DKA.30,31 With the advent of more 
sophisticated technology, it was expected that mechanical pump failures would be less 
frequent—though this has not been found to be the case.32,33 A recent study based on 
patient responses to a standardized questionnaire showed that, even with current 
modern insulin pump technology, problems with the infusion set, infusion site and pump 
itself are still common, with most problems occurring within the first year of IPT.32 The 
most common infusion set problems were kinking and blockage, the most common 
infusion site problem was lipohypertrophy (occurring with long duration of IPT use), and 
the most common pump problems were “no delivery”, keypad and battery problems.32 
Guilhem et al.33 prospectively examined the occurrence of insulin pump failures over 6 
years, and found that pump failure still occurs frequently, but with an important 
difference as compared to the early days of IPT: despite the frequent occurrence of 
pump failure, the major metabolic consequence of pump failure, DKA, was not seen in 
the majority of patients.33 It was speculated that patient education and availability of 24-
hour on-call assistance were instrumental in helping to limit the development of DKA 
after pump failure. These studies highlight the importance of appropriate education and 
training for patients on IPT to help them recognize technical pump problems, and avoid 
adverse consequences when they do develop.  
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2.5.2 Chronic Complications of Uncontrolled Type 1 Diabetes 
The chronic complications of T1DM can be classified as microvascular, macrovascular or 
both.  The major microvascular complications are retinopathy and nephropathy, while 
the major macrovascular complications are coronary artery disease (CAD), 
cerebrovascular disease (CVD), and peripheral vascular disease (PVD). Neuropathy can 
be caused by both microvascular and macrovascular pathology.   
Microvascular Complications 
Strict glycaemic control can prevent the development of, or slow the progression of, 
microvascular complications and neuropathy. In the DCCT,26 intensive therapy targeting 
normoglycaemia both prevented the development and slowed the progression of 
microvascular endpoints and neuropathy in people with T1DM.26 Intensive therapy 
reduced the risks of the development of retinopathy by 76% and the progression of 
retinopathy by 54%, and also reduced the occurrence of microalbuminuria, albuminuria, 
and clinical neuropathy by 39%, 54% and 60%, respectively, in patients with T1DM.26    
Retinopathy 
Diabetic retinopathy is a broad term for damage to the retina caused by changes in the 
retinal blood vessels in patients with diabetes, clinically characterized by the presence of 
specific retinal lesions. In 2012, the estimated worldwide age-standardized prevalence of 
any diabetic retinopathy was 77.3%, while that of vision-threatening retinopathy was 
38.5%, in those with T1DM.34 In Canada, diabetic retinopathy is the main cause of 
blindness in adults aged 30-69 years.35 However, detection and treatment of diabetic 
retinopathy can decrease the risk of vision loss, and thus routine annual screening is 
recommended for all people with T1DM starting 5 years after diagnosis.2 Treatment 
options for retinopathy include laser therapy, vitrectomy, or intraocular pharmacological 
therapy.  
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Nephropathy 
Diabetic nephropathy is defined as damage to the glomeruli of the kidney caused by 
diabetes, resulting in increasing urinary protein excretion and subsequent impairment of 
renal function. Diabetic nephropathy is the leading cause of end-stage renal disease 
(ESRD) in Ontario and in Canada, with over 25% of the cases of ESRD attributed to 
diabetes, both provincially and nationally.36 Annual screening for nephropathy is 
recommended in T1DM starting 5 years after diagnosis.2 If nephropathy is present (or if 
absent but the patient is hypertensive), medications to block the renin-angiotensin-
aldosterone system are of benefit. In normotensive patients with37-42 or without41 
microalbuminuria, as well as in patients with overt nephropathy,43 treatment with 
angiotensin-converting enzyme (ACE) inhibitors has been shown to slow the progression 
of nephropathy. This benefit appears to occur independently from the effect of ACE 
inhibitors in lowering blood pressure.44 Similarly, treatment with angiotensin II-receptor 
blockers has been shown to slow nephropathy progression.45  
Neuropathy 
Diabetic neuropathy is comprised of a range of disorders involving nerve damage due to 
diabetes. Population-based studies have shown that peripheral and autonomic 
neuropathy in adults with T1DM is common with prevalences of 66% and 54%, 
respectively.46,47 Similar to the recommendations for retinopathy and nephropathy 
screening, peripheral neuropathy screening is recommended annually starting 5 years 
after diagnosis of T1DM.  As demonstrated in the DCCT,26 strict glycaemic control is key 
in preventing and slowing progression of neuropathy, but if neuropathy is painful, 
symptomatic relief may be attempted using anticonvulsants, antidepressants, opioids, or 
topical nitrate spray.2  
Macrovascular Complications 
Strict glycaemic control has also been shown to be important in reducing the risk of 
cardiovascular disease in T1DM. The DCCT demonstrated a non-significant trend toward 
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decreased cardiovascular events with intensive therapy targeting normoglycaemia.48 
The Epidemiology of Diabetes Interventions and Complications (EDIC) study49 is a long-
term follow-up observational study to the DCCT, and it showed that intensive therapy 
was associated with a 42% reduction in the risk for any cardiovascular disease event and 
a 57% reduction in risk for the combined outcome of non-fatal myocardial infarction, 
stroke, or death.  
In addition to glycaemic control, other important measures to reduce cardiovascular risk 
in T1DM are lifestyle and pharmacologic measures in the management of obesity, 
hypertension and dyslipidemia, including physical activity and attention to diet, as well 
as smoking cessation.2 
2.5.3 Hypoglycaemia 
Hypoglycaemia is a common consequence of insulin treatment. Clinically, it is 
characterized by Whipple’s Triad: 1) the presence of autonomic or neuroglycopenic 
symptoms, 2) a plasma glucose level <4.0 mmol/L, and 3) resolution of symptoms with 
administration of carbohydrate. The severity of hypoglycaemia is classified as follows 
according to the type of symptoms present and whether the patient is able to self-treat: 
mild – autonomic symptoms and patient can self-treat, moderate – autonomic and 
neuroglycopenic symptoms and patient can self-treat, severe – patient requires the 
assistance of another person to treat.2 Risk factors for severe hypoglycaemia in patients 
with T1DM include prior hypoglycaemia, especially tight glycaemic control as reflected 
by a current A1C <6.0%, hypoglycaemic unawareness, long duration of T1DM, and 
autonomic neuropathy.2 Severe hypoglycaemia in T1DM is common, with prior studies 
reporting a prevalence between 30-40% per year,50-52 and an incidence between 1.15-
3.20 events per person per year.53,54 Hypoglycaemia can have a profound negative 
impact on quality of life, and can discourage patients from striving to achieve tight 
glycaemic control.  
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2.6 Insulin in Type 1 Diabetes Mellitus 
Insulin is the mainstay of treatment in T1DM. There are a variety of insulin formulations 
available in Canada with varying onset and peak duration of action (Table 1). The current 
standard of care for intensive insulin therapy is use of either an MDI regimen or 
continuous subcutaneous insulin infusion with an insulin pump.2 
Insulin injections may be administered using syringes and needles or specially designed 
insulin pens. In MDI regimens, a basal dose of insulin is given by injection with an 
intermediate-acting insulin or a long-acting insulin analogue once or twice a day, while 
bolus doses of insulin are given by injection with a short-acting insulin or a rapid-acting 
insulin analogue at each meal.2 The goal of MDI regimens is to simulate normal 
pancreatic secretion of insulin. 
 
Table 1 – Insulin Formulations Available in Canada 
Insulin Type Generic and Brand Names Basal or 
Bolus 
Pharmacokinetics 
Long-acting basal 
analogues 
Glargine (Lantus) 
Detemir (Levemir) 
Basal Onset: 90 minutes 
Peak: Not applicable 
Duration: up to 24 hours 
Intermediate-
acting 
 
Humulin-N 
Novolin ge NPH 
Basal Onset: 1-3 hours 
Peak: 5-8 hours 
Duration: up to 18 hours 
Short-acting 
 
Humulin-R 
Novolin ge Toronto 
Bolus Onset: 30 minutes 
Peak: 2-3 hours 
Duration: 6.5 hours 
Rapid-acting 
analogues 
Aspart (NovoRapid) 
Lispro (Humalog) 
Glulisine (Apidra) 
Bolus Onset: 10-15 minutes 
Peak: 1-2 hours 
Duration: 3-5 hours 
Pre-mixed Humalog Mix 25 
NovoMix 30 
Humulin (30/70) 
Novolin ge (30/70, 40/60, 50/50) 
  
 
Adapted from the Canadian Diabetes Association 2009/10 Consumer’s guide to diabetes 
products and medications12 
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Continuous subcutaneous insulin infusion with an insulin pump usually uses rapid-acting 
analogues. Similar to MDI, IPT strives to mimic physiologic insulin secretion by the 
pancreas by providing a continuous basal infusion of insulin throughout the day, with 
boluses given as needed by the patient for meals.  
The first subcutaneous insulin pump developed was the “Mill Hill infuser”, described in 
1977 by Parsons et al.55 The first use of continuous subcutaneous insulin infusion in 
patients with T1DM was in the United Kingdom56 and the United States.57 
The current subcutaneous insulin pumps consist of a cartridge (reservoir) which may 
hold up to 300 units of insulin, the pump mechanism (electronic computer components, 
motor, piston), a battery, display screen and function buttons, and an infusion set 
containing a small flexible cannula that is inserted under the skin (Figure 1). The original 
insulin pumps were large, measuring 18.3 x 7.3 x 6.4 cm and weighing up to 400 grams.58 
However, over the past 35 years the technology has greatly improved such that the 
current pumps are much smaller and lighter (measuring approximately 8 x 5 x 2 cm and 
88-110 grams).12 Current insulin pumps also have features for easier use, including the 
ability to program multiple different basal rates of insulin delivery through the day, 
bolus calculator functions to help calculate the appropriate bolus dose according to the 
number of grams of carbohydrate consumed, and memory displays of insulin delivery. 
As the technology develops further, more sophisticated pump features are being offered 
including insulin pumps combined with continuous glucose monitoring systems (CGMS). 
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Given the sophisticated features of modern insulin pumps, patients pursuing IPT must 
undergo specialized training and education to learn not only the basics of using a pump 
(i.e. infusion set insertion, basal rate programming and bolus dose delivery), but also 
troubleshooting skills to manage technical pump problems. In addition, the usual 
components of routine diabetes management are still required (i.e. frequent capillary 
blood glucose monitoring, accurate carbohydrate counting at meals and snacks, 
appropriate sick day management etc.). 
 
2.7 Insulin Pump Therapy and Type 1 Diabetes Mellitus 
2.7.1 Evidence for the Efficacy of Insulin Pump Therapy in Adults with Type 1 Diabetes 
Mellitus  
Many randomized controlled trials (RCTs) comparing the efficacy of IPT and MDI 
programs in improving glycaemic control in T1DM have been performed, and several 
meta-analyses have been done in recent years.3-11 All of the meta-analyses have shown a 
Figure 1 – Schematic of Insulin Pump and Related Supplies 
Reproduced with permission from Didangelos T 2011 Diabetes Res Clin Pract 59 
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small but significant improvement in A1C levels  with IPT as compared to MDI, though 
the meta-analyses varied in the studies included, age of subjects (children and/or 
adults), and types of insulin used in the MDI regimen (i.e. short and intermediate–acting 
insulins vs. rapid and long-acting insulin analogues).3-11  
Although it was not designed to compare the efficacy of IPT and MDI in achieving strict 
glycaemic control, the DCCT provided observational evidence from the intensive therapy 
group, who self-selected to either IPT or MDI.60 When data from participants with at 
least 4.5 years of follow-up were analyzed according to mode of insulin delivery (IPT n = 
124, MDI n=284), the IPT subgroup achieved A1C levels between 0.002-0.004 (i.e. 0.2-
0.4%) lower compared to the MDI subgroup with both subgroups being similar in 
important clinical and demographic characteristics (age, duration of T1DM, baseline 
A1C).60  
However, despite the RCT evidence supporting a beneficial effect of IPT use in improving 
glycaemic control, there is limited observational evidence on the benefits of IPT in 
routine clinical practice. It is not disputed that results from RCTs provide the strongest 
level of evidence in answering a question about an intervention’s efficacy, but it is often 
noted that RCT results may be less useful in answering the question of whether the 
intervention works in routine clinical practice. The subjects of RCTs are usually a highly 
selected and homogeneous population (as a result of strict inclusion and exclusion 
criteria), and the intervention studied is given in a standardized manner under ideal 
settings.  These conditions are not the norm in the “real-world”.  Outside of a RCT, 
factors other than the intervention can influence the intervention’s effectiveness 
including patient-specific and provider-specific factors. 
Despite the meta-analyses of RCTs noted above that have shown a significant benefit of 
IPT on glycaemic control, worldwide uptake of IPT use is variable. To our knowledge, 
there have been 19 observational studies61-79 (17 prospective or retrospective cohort 
studies, 2 cross-sectional studies) evaluating the association between IPT and glycaemic 
control that, because they were observational, may provide a better indication of the 
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effects of IPT in routine clinical practice (as compared to RCTs).  However, even within 
the observational studies there are differences in design that may not reflect routine 
care ranging from algorithm-based protocol-driven cohort studies63 to studies of data 
from regional71 or national73 IPT registries. Most of these studies have been performed 
in Europe,62,65-68,70,71,73-77,79  with others in the United States,61,63,64 New Zealand,69 
India,72 and Australia.78 No studies have been performed in Canada, and only 2 
studies77,78 had a separate control comparison group of non-IPT users. A summary of 
these observational studies is presented in Table 2. 
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Table 2 – Summary of Observational Studies of the Association Between Insulin Pump Therapy Use and Glycaemic Control 
 
Author 
 (Year) 
Type of Study 
Separate 
Control 
Group? 
Country  
(Data Source) 
# of subjects 
with T1DM on 
IPT 
IPT Duration 
Pre-IPT A1C 
Mean ± SD 
Mean A1C on IPT 
(or change in A1C) 
Mecklenburg
61
 
(1985) 
Prospective 
cohort 
N 
United States  
(3
o
 care centre) 
127 
Mean 31.8 ± 8.37 
mo 
0.106 ± 0.002 
0.089 ± 0.001 (at 1 yr) 
0.089 ± 0.001 (at 2 yrs) 
0.086 ± 0.002 (at 3 yrs) 
Chanteleau
62
 
(1989) 
Prospective 
cohort  
N 
Germany 
(3
o
 care centre) 
116 Mean 4.5 yrs 0.077 ± 0.001 0.067 ± 0.001 
Bode
63
 
(1996) 
Prospective 
cohort  
N 
United States 
(single centre) 
55 Mean 3.1 yrs 0.077 ± 0.015 
0.074 ± 0.012  
(at 1 yr, n=55) 
0.077 ± 0.017 
(at 2 yrs, n=41) 
0.074 ± 0.017 
(at 3 yrs, n=26) 
0.074 ± 0.012 
(at 4 yrs, n=20) 
Rudolph
64
 
(2002) 
Retrospective 
cohort 
N 
United States 
(3
o
 care centre) 
107 
Mean 36.1 ± 25.5 
mo 
0.076 0.071 
Linkeschova
65
 
(2002) 
Prospective 
cohort 
N 
Germany 
(3
o
 care centre) 
103  
(60 for 
optimization, 
43 for severe 
hypo) 
Mean 1.7 ± 1.5 yrs 
(optimization grp) 
Mean 1.9 ± 1.2 yrs 
(severe hypo grp) 
0.078 ± 0.012 
(optimization grp) 
0.076 ± 0.011 
(severe hypo grp) 
0.072 ± 0.008 
(optimization grp) 
0.072 ± 0.012 
(severe hypo grp) 
Nørgaard
66
 
(2003) 
Cross-
sectional 
N 
Denmark 
(nationwide 
audit) 
117 
(87 with pre-
IPT data) 
Mean 13.1 ± 6.3 
yrs 
0.085 ± 0.011 
(n=87) 
0.080 ± 0.012 
(n=87) 
Lepore
67
 
(2005) 
Retrospective 
cohort 
N 
Italy 
(3
o
 care centre) 
82 
Mean 31.9 ± 14.5 
mo 
(range 4-55 mo) 
0.094 ± 0.014 
Mean change 
-0.0115 ± 0.008 
Pickup
68
 
(2006) 
Prospective 
cohort 
N 
United Kingdom 
(3
o
 care centre) 
30 
Median 5 mo 
(IQR 3-9 mo) 
0.085 ± 0.014 0.073 ± 0.900 
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Reda 
69
 
(2007) 
Retrospective 
cohort 
N 
New Zealand 
(3
o
 care centre) 
78 Mean 3.0 ± 2.6 yrs 0.088 ± 0.014 
0.079 ± 0.0100 (at 3 mo) 
0.079 ± 0.0097 (at 6 mo) 
Giménez
70
 
(2007) 
Prospective 
cohort 
N 
Spain 
(3
o
 care centre) 
153 Mean 2 yrs 0.079 ± 0.013 0.073 ± 0.011 (at 2 yrs) 
Riveline
71
 
(2008) 
Cross-
Sectional 
N 
France 
(regional IPT 
registry) 
285 T1DM 
44 T2DM 
Mean 3.5 ± 3.5 yrs 
(total cohort 
n=339) 
0.091 ± 0.019 
(n=339) 
0.078 ± 0.014 
(n=339) 
Sudhakaran
72
 
(2009) 
Retrospective 
cohort 
N 
India 
(3
o
 care centre) 
17 
Mean 2 yrs 
(range 2-6 yrs) 
0.106 ± 0.021 0.080 ± 0.016 
Jankovec
73
 
(2010) 
Retrospective 
cohort 
N 
Czech 
(national IPT  
register) 
730 Minimum 3 yrs 0.0965 ± 0.0007 
0.0824 ± 0.0007 (at 1 yr) 
0.0834 ± 0.0007 (at 2 yrs) 
0.0844 ± 0.0007 (at 3 yrs) 
Janez
74
 
(2012) 
Retrospective 
cohort 
N 
Slovenia 
(3
o
 care centre 
register) 
184 Mean 3.8 ± 0.3 yrs 0.076 ± 0.009 
0.069 ± 0.009 (at 1 yr) 
0.069 ± 0.006 (at 2 yrs) 
0.070 ± 0.006 (at 3 yrs) 
Marmolin
75
 
(2012) 
Cohort 
(retrospective 
& prospective 
data) 
N 
Denmark  
(3
o
 care centre 
database) 
68 
2.2 yrs 
(range 0-25 yrs) 
0.080 
(range 
0.058-0.137) 
0.076 
(range 0.061-0.095) 
(median follow-up 3 yrs) 
Crenier
76
 
(2013) 
Retrospective 
cohort 
N 
Belgium 
(3
o
 care centre) 
50 6 mo 0.0804 ± 0.0116 0.0748 ± 0.009 (at 6 mo) 
Carlsson
77
 
(2013) 
Retrospective 
cohort 
Y 
Sweden (EMR 
from 10 clinics) 
272 Minimum 5.5 yrs 0.0839 ± 0.0130 
Mean change at 1 yr: 
-0.0054 
Cohen
78
 
(2013)  
Retrospective 
cohort 
Y 
Australia 
(3
o
 care centre) 
126 6 mo 0.080 ± 0.01 
Mean change: 
-0.0064 (at 6 mo, n=117) 
-0.0060 (at 1 yr, n=102) 
Grant
79
 
(2013)  
Cohort 
(retrospective 
& prospective 
data) 
N 
United Kingdom 
(3
o
 care centre) 
350 
Range 
6-12 mo 
0.078 
(total cohort 
n=350) 
Mean change -0.010 
(those without mental 
health problems: n=171) 
 
T1DM, type 1 diabetes mellitus; IPT, insulin pump therapy; A1C, glycated hemoglobin; SD, standard deviation; Y, yes; N, no; 3
o
,tertiary; mo, months; yr, year; 
grp, group, hypo, hypoglycaemia; EMR, electronic medical record 
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2.7.2 “Real-World” Insulin Pump Therapy Use in Type 1 Diabetes Mellitus 
The use of IPT in patients with T1DM varies worldwide but remains low in many 
countries. Recent nationwide audits in the United Kingdom80,81 and Australia82 have 
shown the prevalence of IPT use in T1DM to be 2-6% and 10%, respectively.   
In Europe, reported IPT use rates in T1DM vary from <5% in Finland, Portugal, Spain, and 
Russia,83,84 5-10% in Belgium, Czech Republic, Denmark, Greece, Hungary, Ireland, Italy, 
Poland, and Slovakia,84 and >15% in Austria, France, Germany, the Netherlands, Norway, 
Sweden and Switzerland.83-85   
There are limited data on IPT use rates in T1DM in Asia, which may be related to the 
small proportion of patients with T1DM in many Asian countries.  In India, over 95% of 
patients with diabetes have T2DM, and so IPT is used primarily in this population, with 
only ~20% of IPT use in T1DM.86 Similarly, in China, only 30% of IPT use is in T1DM.87   
The highest rate of IPT use in T1DM is in North America. In the United States, it is 
estimated that ~40% of patients with T1DM use IPT.83 In Canada, the IPT use rate is 
estimated to be between ~8-15% of eligible people (children and adults).88  
The large variability in IPT use worldwide may be related to many factors, but 
worldwide, a large barrier to IPT use remains the costs to patients and the health care 
system. The major cost of IPT to the patient is the insulin pump and its associated 
supplies, while the main costs to the health care system arise from delivery of IPT-
related services.80  
2.7.3 Funding for Insulin Pump Therapy in Type 1 Diabetes Mellitus in Canada 
In Canada, government funding to patients with T1DM for IPT and its associated supplies 
is province-specific (Appendix A). Ontario was the first province to implement IPT 
funding for children beginning January 2007 (retroactive to April 1, 2006). In September 
2008, Ontario was also was the first province to initiate IPT funding for eligible adults 
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through the MOHLTC ADP, with eligibility determined based on pre-specified clinical 
criteria. The ADP collects demographic, glycaemic control and adverse event data (i.e. 
hypoglycaemia) at program entry and on annual renewal. 
Until very recently, Ontario was the only province to provide IPT funding to adults 
(Alberta began IPT funding for residents of any age in June 2013). Prince Edward Island 
remains the only province without funding for IPT (child or adult), while the other 
provinces and territories only have coverage for children and young adults, with 
differing age limits, eligibility criteria, coverage for pump supplies, and amount of 
funding.  
In Ontario, the ADP provides coverage for the full cost of the insulin pump on initial 
application paid directly to the insulin pump supplier. The ADP also provides program 
participants with a grant of $2,400.00 CAD per year (divided into quarterly payments) for 
IPT-associated supplies. 
 
2.8 Insulin Pump Therapy for Type 1 Diabetes Mellitus in London, Ontario 
Care for adults with T1DM may be managed by Family Physicians, General Internists, or 
Endocrinologists. As a tertiary care referral centre for Southwestern Ontario, SJHC 
provides a regional resource for care of T1DM, and is the main IPT provider site for the 
ADP within the South West Local Health Integration Network (Appendix B). 
At SJHC, adults with T1DM who are interested in pursuing IPT through funding by the 
ADP may be seen by 1 of 12 adult Endocrinologists in the Division of Endocrinology & 
Metabolism at St. Joseph’s Hospital or by 1 of 2 Family Physicians with expertise in 
diabetes at the PCDSP.  To initiate the process, interested patients attend a “Pump 
Information Class” held at the Diabetes Education Centre (DEC). They are then referred 
by their physician for individual consultations with a registered IPT nurse (RN) and 
dietitian (RD) at the DEC for a “Pre-ADP Assessment”. As part of this assessment, 
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patients must demonstrate that they meet the ADP eligibility criteria (Appendix C). After 
meeting the eligibility criteria, patients attend a “Pre-Pump Start Class” and 
subsequently a “Pump Start Class” at the DEC, at which time they begin a 90 day trial 
period of IPT. Once the trial has begun, their physician submits an application form on 
their behalf to the ADP. On this form, clinical data on glycaemic control and adverse 
events in the year prior are collected (2-3 most recent A1C values, number of episodes 
of DKA and severe hypoglycaemia) (Appendix D).  Other collected information includes 
demographics, confirmation of eligibility, and the make and model of insulin pump 
chosen by the patient. If the trial period is completed successfully, patients then 
schedule follow-up education classes and individual RN and RD appointments as needed.  
If a patient wishes to continue ADP-funded IPT past the first year, they must apply for a 
renewal. To do so, they must continue to meet specific ongoing eligibility criteria 
(Appendix C), and their physician is required to submit a renewal form to the ADP, 
including their last 2 A1C values and number of hypoglycaemic episodes requiring third-
party intervention (Appendix E). Application for repeated renewal of IPT funding is 
required annually thereafter.  Continued close contact with the patient’s diabetes 
management team (physician, RN and RD) is required throughout the duration of their 
participation in the program. 
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2.9 Summary 
2.9.1 Research Question and Hypothesis 
The main research question of this study was: does ADP-funded IPT improve glycaemic 
control and adverse outcomes in adults with T1DM followed by the Diabetes Clinics at 
SJHC? 
It was hypothesized that ADP-funded IPT would improve glycaemic control and adverse 
outcomes in adults with T1DM, as compared to adults with T1DM not on IPT, who are 
followed by the Diabetes Clinics at SJHC. 
2.9.2 Significance of the Research 
Use of IPT for the management of T1DM is increasing.  Clinical trials have shown that IPT 
significantly improves glycaemic control in adults with T1DM as compared to insulin 
treatment by MDI, though there is limited observational evidence on the benefits of IPT 
in routine clinical practice in Canada, and any potential benefits may be highly 
dependent on appropriate patient selection. Further, a major barrier that precludes 
widespread use of IPT is the cost. 
Ontario has been a leader in Canada in implementing funding for IPT—first for children, 
and now adults. From the inception of the adult program in September 2008 until 
December 31, 2012 the ADP has received 7,363 applications from adults in Ontario 
seeking funding for IPT. However, to date, there has been no evaluation of the clinical 
impact of ADP-funded IPT.    
This study is the first to evaluate the effect of a provincially-funded program for insulin 
pump therapy on glycaemic control and adverse outcomes in adults served by a tertiary 
care diabetes referral centre in Canada. 
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Chapter 3: Methods 
3.1 Overview of Study Design 
This study used a retrospective single-centre observational matched cohort design using 
data from WebDR, the EMR system of the Diabetes Clinics at SJHC in London, Ontario, 
and from physician paper charts. Patients with T1DM were identified, and from these 
patients, a cohort of subjects on IPT was selected and individually matched to subjects 
not on IPT, resulting in matched pairs of IPT subjects and control subjects (as described 
below). Demographic and clinical characteristics were compared between the IPT and 
control cohorts, while glycaemic control outcomes and adverse events were compared 
for each pair before and after the IPT start date of each pair’s IPT subject. 
 
3.2 Ethics Approval 
This study was approved by the Western University Health Sciences Research Ethics 
Board (Appendices F and G). No patient contact occurred and informed consent was not 
required as the data used was secondary data collected as part of routine clinical care.    
 
3.3 Data Sources 
WebDR is a web-based EMR database system that was developed for clinical and 
research use at SJHC (Appendix H).  WebDR was populated from migration of data from 
the DAD (a prior EMR used by select Diabetes Clinics in London over the past decade) 
and by manual data entry from physician paper charts (performed in 2010-2011).  Thus, 
WebDR contains patient data from as early as 2000.  
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Routine clinical use of WebDR began in September 2011 at the PCDSP and in October 
2011 at St. Joseph’s Hospital.  All patients seen at the Diabetes Clinics are assigned a 
unique WebDR identification number and demographic, clinical, and laboratory data are 
entered and/or updated at each visit by physicians, including residents, allied health 
professionals (nurses and dietitians) or by a dedicated medical data entry clerk.  As of 
March 2013, WebDR contained clinical data from 15,478 patients with diabetes, of 
whom 12,046 had information on type and duration of diabetes.   
The researchable database of WebDR is a repository of de-identified data which is 
stored on a separate server from the clinical application for security and confidentiality 
purposes. However, the repository and clinical application are linked to allow for daily 
data updates. There is one dedicated Database Manager with the unique ability to 
perform queries of the researchable database. 
For this study, data was extracted from WebDR. However, as this was the first use of 
WebDR for research, for all data extraction the WebDR data was compared to the 
physician paper chart to ensure accuracy and completeness of the study data. Where 
WebDR data was missing or different compared to the physician paper chart, data from 
the physician paper chart was extracted and used in the analyses.  
Validation of WebDR data was performed (Appendix I). The gold standard for 
comparison was the physician paper chart. A random sample of 10% of the study cohort 
records was selected for validation, with 4 variables selected for validation (baseline A1C 
value, baseline A1C date, follow-up A1C value, follow-up A1C date). Accuracy was 
assessed according to 3 levels of agreement (match, no match, not recorded). 
The overall level of agreement between WebDR and the reference standard was fair to 
good, with a range of matches from 69.4% to 80.6%. There were no instances of “no 
match”; however, the range of “not recorded” values was 19.4% to 30.6%.  
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For all patient records, after completion of the validation, the data found to be missing 
in WebDR were extracted from the physician paper chart and subsequently entered into 
WebDR to improve its accuracy for future research use. 
 
3.4 Study Population and Cohort Selection 
The target population consisted of all adults age ≥ 19 years with T1DM followed by the 
Diabetes Clinics at SJHC and who were entered into WebDR.  Subjects on IPT (the insulin 
pump therapy cohort) were entered into the study at their IPT start date (which could 
be any time between September 1, 2008 and August 31, 2011) and data from 18 months 
prior to their IPT start date until October 15, 2012 was collected. The time frame for IPT 
start date was chosen to (a) coincide with the start of the Ontario MOHLTC ADP funding 
of IPT for adults, and (b) to allow for data to be collected up until at least 13.5 months 
after the latest possible IPT start date (i.e. August 2011). This minimum 13.5 month 
follow-up period was chosen to allow for assessment of the primary outcome (glycated 
hemoglobin, or A1C) at 1 year, and since A1C  is an estimate of glycaemic control over ~ 
3 months, a window of 12 ± 1.5 months was selected. Subjects not on IPT (the matched 
control cohort) were entered into the study according to the IPT start date of the pump 
cohort subject to whom they were matched, and data from 18 months prior to study 
entry until October 15, 2012 was collected.  Subject follow-up length was variable 
(Figure 2).
  
IPT, Insulin Pump Therapy; ADP
 
Figure 2 – Timeframes for I
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start class notification form (preferred) or a clinic progress note which documented the 
IPT start month and year.  
Only those patients who started IPT in September 2008 or later were considered for 
inclusion, as this was the start month of the Ontario MOHLTC funding of IPT through the 
ADP.  Confirmation of IPT use was performed by cross-reference to the list of patients 
who started on IPT maintained by the SJHC DEC. It was judged that this was an accurate 
independent method of verification of IPT use during the time period of interest as it 
was mandatory for all patients starting on ADP-funded IPT to be seen by an insulin pump 
nurse and dietitian at the DEC prior to initiation of IPT. 
3.4.3 Assembly of the Matched Control Cohort 
Subjects not on IPT (and thus potential control subjects) were identified among 
remaining patients with T1DM in WebDR who were not identified by the WebDR to be 
using IPT. A WebDR query was performed to generate a list of these subjects, along with 
their current age, and current duration of T1DM.  
This study examined the relationship between IPT use and glycaemic control. As there 
are many potential confounding factors for this relationship (i.e. factors associated with 
both IPT use and with glycaemic control), matching was used to limit confounding bias. 
The primary matching variable was duration of T1DM. The secondary matching variables 
were current age and year of study entry. Matches were identified manually as 
described below. 
Control subjects were matched to IPT subjects starting with exact duration of T1DM in 
years, and then matched as closely as possible for current age in years measured as the 
absolute difference between the age of the IPT subject and the control subject.  In 
situations where there was more than 1 potential control subject with the same 
absolute age difference compared to the IPT subject (e.g., if a potential control subject 
was 2 years younger and another was 2 years older), the older subject was selected as 
the matched control. If there was more than 1 potential control subject with the same 
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age difference compared to the IPT subject (e.g.  both were 2 years younger), the first 
subject on the list was selected. The date of study entry of control subjects was the “t=0 
date”, which was defined as the corresponding IPT start date of the IPT subject to whom 
they were matched. 
3.4.4 Inclusion Criteria 
Patients were included if they were age ≥ 19 years of age at the time of study entry and 
had a known diagnosis of T1DM for at least 1 year prior to study entry. The rationale for 
only including those with T1DM for ≥ 1 year was that a) glycaemic control in the first 
year after diagnosis may not necessarily be representative of long-term glycaemic 
control, b) data from at least 1 year prior to study entry was required and c) to be 
eligible to apply for ADP-funded IPT, patients had to demonstrate experience on an MDI 
regimen for at least 1 year.  It was also required that patients had a paper chart available 
for review, and were actively followed by a SJHC physician during the time period of 
interest. 
Patients on IPT were included in the IPT cohort if they began IPT through the Diabetes 
clinics at SJHC at age ≥ 19 years at some point between September 1, 2008 and August 
31, 2011, and remained on IPT for at least 1 year.  The rationale for these requirements 
were that a) those who started IPT during this time were likely to have done so via ADP 
funding, and b) data from 1 year after IPT start was required.  
3.4.5 Exclusion Criteria 
Patients were excluded if they a) were pregnant within 1 year prior to or within 1 year 
after study entry, b) did not have a documented baseline A1C level  within 18 months 
before study entry or c) did not have any documented follow-up A1C measurements 
after study entry. Pregnancy was a reason for exclusion as it is a time during which 
stricter glycaemic targets are recommended.2 
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Figure 3 – Definition of Primary Outcome
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follow-up for adverse events was based on the calendar year).  Severe hypoglycaemia 
was defined as hypoglycaemia requiring 3rd-party assistance.2 Adverse events were 
continuous variables obtained via patient self-report, and were reported as incidence 
rates separately for each type of event at baseline and at each follow-up year.  
 
3.6 Cohort Characteristics – Insulin Pump Therapy and Control Cohorts 
The following demographic and clinical characteristics were collected from WebDR 
and/or physician paper charts at baseline, or at baseline and follow-up, for the IPT and 
control cohorts: current age, gender, access to private drug plan, city of residence, 
average yearly household income, physician of record, current duration of T1DM, 
smoking status, complication status, body mass index (BMI), total daily insulin dose 
(TDD), number of capillary blood glucose (CBG) monitoring checks per day, number of 
insulin injections per day, CGMS use, and number of adverse events per year. Baseline 
characteristics were those documented in the calendar year prior to the IPT start 
year/t=0 year, while follow-up characteristics were those documented in the calendar 
year after the IPT start year/t=0 year. 
3.6.1 Demographic Characteristics 
Current age 
Current age was a continuous variable in years derived from the patient self-reported 
year of birth.  Current age was calculated as 2013 – (year of birth). The year 2013 was 
chosen as the reference year for calculating the current age since data analysis was done 
in the year 2013. 
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Gender 
Gender was coded as a dichotomous variable with 1 representing males and 0 
representing females. 
Access to Private Drug Plan 
Access to a private drug plan at baseline was defined as access to any non-Ontario 
Health Insurance Plan drug insurance coverage, and was obtained via patient self-report. 
It was coded as a dichotomous variable, with 1 for “yes” and 0 for “no”.   
City of Residence 
City of residence at baseline was obtained via patient self-report. It was coded as a 
dichotomous variable with 1 for London and 0 for any other city. 
Average Yearly Household Income 
Average yearly household income at baseline was a continuous variable in dollars 
derived from linkage of patient self-reported postal code to data from the 2006 Census 
of Canada. The Census of Canada obtains address information (including postal code) 
and data on household income for each respondent allowing for calculation of average 
yearly household income at the Forward Sortation Area (FSA) level, which is the first 3 
characters of the postal code (as defined by Canada Post). Data from the 2006 Census of 
Canada was obtained via Western University’s Equinox data delivery system.  
Physician of Record 
The physician of record was the physician responsible for the patient’s diabetes care. 
The variable was categorized into a dichotomous variable as per the physician specialty, 
with 1 for Endocrinologist and 0 for Family Physician. 
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3.6.2 Clinical Characteristics 
Current duration of T1DM 
Current duration of T1DM was a continuous variable in years derived from either the 
patient self-reported year of T1DM diagnosis or the patient self-reported age at T1DM 
diagnosis. If the year of T1DM diagnosis was available, current duration of T1DM was 
calculated as 2013 – (year of T1DM diagnosis). As above, 2013 was used as the reference 
year since data analysis was done in 2013. If the age at T1DM diagnosis was available, 
the year of T1DM diagnosis was calculated as (year of birth) + (age at T1DM diagnosis), 
and then duration of T1DM subsequently calculated.  
Smoking status 
Smoking status at baseline was obtained via patient self-report, and coded as a 
dichotomous variable with 1 for “current smoking” and 0 for “no current smoking”. 
Complication Status 
The complication status at baseline was obtained via patient self-report. The specific 
complications were cerebrovascular disease, coronary artery disease, peripheral 
vascular disease, retinopathy, nephropathy and neuropathy, and were each coded as a 
dichotomous variable with 1 for “presence of complication” and 0 for “absence of 
complication”. The frequency of each complication was reported separately, and also 
reported grouped into the dichotomous variables “at least 1 complication” (defined as 
the presence of any 1 or more complication) and “at least 1 glycaemic-responsive 
complication” (defined as the presence of at least 1 of retinopathy, nephropathy or 
neuropathy), with 1 for “presence” and 0 for “absence”. 
Body Mass Index 
Body Mass Index (BMI) was a continuous variable in kg/m2 derived from the height and 
weight of each patient (calculated as weight/height2). Data on BMI was collected at 
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baseline and at yearly follow-up. Height was either patient self-reported or measured at 
the initial clinic visit, and weight was measured by clinic staff at each clinic visit. 
Total Daily Insulin Dose  
The total daily insulin dose (TDD) at baseline was a continuous variable in units derived 
from the patient self-reported basal and bolus insulin doses. It was calculated as (total 
basal insulin doses per day) + (total bolus insulin doses per day). 
Capillary Blood Glucose Monitoring Checks 
The number of capillary blood glucose monitoring checks (CBG) per day, at baseline and 
at yearly follow-up, was a continuous variable obtained via patient self-report. 
Insulin Injections 
The number of insulin injections per day, at baseline (IPT cohort) or at baseline and 
yearly follow-up (control cohort), was a continuous variable obtained via patient self-
report. 
CGMS Use 
Use of a CGMS was a dichotomous variable, obtained via patient self-report. It was 
defined as “ever CGMS use”, with 1 for “yes” and 0 for “no”. 
 
3.7 Insulin Pump Therapy-Related Characteristics 
For the IPT cohort, the following IPT-related characteristics were collected:  age at IPT 
start, brand of insulin pump, year of ADP application, year of insulin pump trial start and 
wait time from DEC referral to DEC appointment for the ADP process. 
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3.7.1 Age at Insulin Pump Therapy Start 
Age at insulin pump therapy start, in years, was a continuous variable derived from the 
documented year of insulin pump therapy start (from WebDR or physician paper chart) 
and patient self-reported year of birth, calculated as (year of pump start) – (year of 
birth). 
3.7.2 Brand of Insulin Pump 
The brand of insulin pump was a categorical variable obtained from a copy of the initial 
MOHLTC ADP insulin pump application form in the physician paper chart. If this was not 
available, data on brand of insulin pump was extracted from clinic progress notes. The 
variable was coded as 1 for Medtronic, 2 for Animas or 0 for other. 
3.7.3 Year of ADP Application and Year of Insulin Pump Trial Start 
Year of ADP application and year of insulin pump trial start were coded as categorical 
variables based on the calendar year of the dates of ADP application and insulin pump 
trial start documented on a copy of the initial MOHLTC insulin pump ADP application 
form in the physician paper chart.  Years were coded as follows: 0 for 2008, 1 for 2009, 2 
for 2010, 3 for 2011 and 4 for missing. Of note, the variables 2008 and 2011 were not 
full 12 month years, given that window for IPT start date was from September 2008 until 
August 2011, so the variable 2008 represents data from 4 months (September-
December 2008) and 2011 represents data from 8 months (January-August 2011), while 
the variables 2009 and 2010 represent data from the full 12 month calendar years. 
Further, whether a copy of the initial MOHLTC insulin pump ADP application form was 
kept in the paper chart varied by physician, and therefore some data on year of ADP 
application and year of insulin pump trial start was missing.   
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3.7.4 Wait time from DEC Referral to Appointment  
Wait time from DEC referral to appointment in months was a continuous variable based 
derived from the dates of DEC referral and DEC appointment documented in a copy of 
the initial MOHLTC insulin pump ADP application form in the physician paper chart. 
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3.8 Power Calculation  
An a priori power calculation was performed prior to the start of the study. It was 
estimated that between 100-250 adults with T1DM from the Diabetes Clinics at SJHC 
were on ADP-funded IPT. Given this range in sample size, assuming α=0.05 and β=0.20, 
and estimating the standard deviation of the mean change in A1C over 1 year to be 
0.00048, or 0.048% (as per WebDR data from all adult patients with T1DM in 2010), the 
smallest detectable difference in the mean change in A1C over 1 year between the IPT 
and control cohorts was between 0.00019, or 0.019% (for n=100 per group) and 
0.00012, or 0.012% (for n=250 per group) (Table 3). 
 
Table 3 – Power Calculation and Smallest Detectable Difference in Change in A1C 
SD of change 
in A1C (σ∆) 
Sample Size Per Group 
50 100 150 200 250 300 
0.048% 0.027% 0.019% 0.016% 0.013% 0.012% 0.011% 
      
δ
2
 = [(Z
α
+Z
β
)
2 
* 2σ
Δ
2
]/n  
where: 
 
Δ
c
 = mean change in A1C in control cohort over 1 year 
Δ
p
 = mean change in A1C in IPT cohort over 1 year 
σ
Δ
 = SD of change in A1C over 1 year = 0.048%  
δ = smallest detectable difference between Δ
c
 and Δ
p
 
n = sample size per group 
 
and assuming α = 0.05, β = 0.20 
       
SD, standard deviation; A1C, glycated hemoglobin; IPT, insulin pump therapy 
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3.9 Statistical Analysis 
Statistical analysis was performed using SAS for Windows (version 9.3). Demographic 
and clinical characteristics were summarized using means and standard deviations or 
proportions where applicable. The level of significance for all statistical tests was 0.05, 
unless otherwise stated. 
3.9.1 Comparison of Included and Excluded IPT Subjects 
The age, duration of T1DM and gender of the included and excluded IPT subjects were 
compared using independent samples t-tests (means) or Chi-square test (proportions), 
as appropriate. 
3.9.2 Paired Comparisons 
Paired comparisons were performed to compare the current demographic 
characteristics and baseline clinical characteristics of the IPT and control cohorts, using 
paired t-tests (means) or McNemar’s test (proportions) as appropriate. Paired t-tests 
were also performed to compare the mean A1C at baseline and follow-up and the mean 
difference in A1C change scores between the IPT and control cohorts. McNemar’s test 
was used to compare the proportions of subjects with an optimal A1C at baseline and 
follow-up within each cohort, and to compare the proportions of subjects with an 
optimal A1C between the IPT and control cohorts. Negative binomial regression was 
used to compare the incidence of adverse events between cohorts at baseline (i.e. 1 
year pre-IPT start/t=0) and at each follow-up year. 
3.9.3 Missing Data and Imputation  
Two pre-specified analyses were performed.  The analyses differed depending on the 
definition of the timing of the follow-up A1C, and whether imputation for missing data 
was performed, as follows: 
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Analysis 1: The follow-up A1C was defined as the A1C value closest to 12 months post-
IPT start/post-t=0 within a window of ± 1.5 months (i.e. 10.5-13.5 months) post-IPT 
start/post-t=0. For subjects without a follow-up A1C between 10.5-13.5 months post-IPT 
start/post-t=0, the missing data were not imputed and they were excluded from the 
analysis. 
Analysis 2: The follow-up A1C was defined as the A1C value closest to 12 months post-
IPT start/post-t=0 within a window of ± 1.5 months (i.e. 10.5-13.5 months) post-IPT 
start/post-t=0. For subjects without a follow-up A1C in this window but who had an A1C 
value between 0 -10.5 months post-IPT start/post-t=0, their follow-up A1C level in the 
analysis was imputed by the “last observation carried forward” (LOCF) method, which 
effectively widened the window for follow-up A1C in this analysis to 0-13.5 months post-
IPT start/post t=0. Those subjects who only had follow-up A1C values >13.5 months 
post-IPT start/post t=0 were excluded from the analysis.  
The proportion of subjects who were missing follow-up A1C values in the IPT vs. control 
cohorts were compared using McNemar’s test. In addition, the baseline characteristics 
of the subjects with missing follow-up A1C data were compared to those subjects with 
non-missing follow-up A1C data within each cohort using two-sample t-tests, Chi-square 
tests, or Fisher’s Exact test, where appropriate. 
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3.9.4 Sensitivity Analyses 
Effect of Wider Age Differences in Age-Matched Pairs 
Since some of the matched IPT-control pairs were not matched within a ± 5 year age 
difference, a sensitivity analysis was done excluding these pairs to determine if a wider 
age difference between IPT-control pairs had an effect on the glycaemic outcomes.  
Effect of Imputing Follow-Up A1C values from <6  Months Post-IPT Start/t=0 
The use of LOCF to impute missing follow-up A1C values assumed that the follow-up, but 
missing, A1C value did not significantly change from when it was measured to when it 
was carried forward. However, since A1C is a measure  of glycaemia over ~3 months, the 
further from the defined 10.5-13.5 month follow-up window that it was measured (i.e. 
the closer to IPT start/t=0), the less likely this assumption was to hold true. Therefore,  a 
sensitivity analysis was done using LOCF of only A1C values measured between 6-10 
months post-IPT start/t=0 to determine if carrying forward values from earlier than 6 
months post-IPT start/t=0 had an effect on the glycaemic outcomes.  
3.9.5 Subgroup Analyses 
Exploratory analyses were done to examine whether the baseline A1C influenced the 
change in A1C from baseline to follow-up in each cohort. The analysis was performed 
separately within each cohort stratified according to baseline A1C into 3 subgroups: ≤ 
0.070, 0.071 to 0.080, and ≥ 0.081. For both the IPT and control cohorts, paired t-tests 
were done to compare the baseline and follow-up A1C in each subgroup. Baseline TDD 
was also calculated for each subgroup and compared by one-way analysis of variance 
(ANOVA) to assess for differences in baseline insulin dose that could contribute to 
differences seen in the change in A1C. If the subgroups were significantly different by 
ANOVA, post-hoc analysis with the Tukey-Kramer test was performed to determine 
which groups differed.   
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Chapter 4: Results 
4.1 Study Cohorts 
4.1.1 Insulin Pump Therapy Cohort 
There were 229 patient records identified by WebDR and 224 patient records identified 
by the DEC list of adults with T1DM who started IPT between September 1, 2008 and 
August 31, 2011. Of these, 105 were common to both sources, resulting in 348 unique 
patient records. Both the WebDR record and physician paper chart record were 
reviewed for 347 of the patients (1 paper chart was not available for review), and 180 
patients were found to meet the inclusion criteria. However, a further 6 patients were 
excluded, resulting in a final IPT cohort of 174 patients (Figure 4). 
Therefore, there were 174 patients on IPT who were not included in the analysis. 
Comparing the final IPT cohort to those IPT patients who were not included in the study 
showed that the patients on IPT who were not included were significantly younger 
(p<0.001), and more likely to be female (p=0.038), but had a similar duration of T1DM 
(Table 4).  
4.1.2 Matched Control Cohort 
Control subjects were first matched to IPT subjects by exact duration of T1DM in years, 
and then by closest age in years. The age differences of the pairs were normally 
distributed, and 84.5% (n=147) of the 174 IPT-control pairs were matched within ± 5 
years (Figure 5).   
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T1DM, type 1 diabetes mellitus; SJHC, St. Joseph’s Health Care; DEC, Diabetes Education 
Centre; A1C, glycated hemoglobin 
Adult patients with T1DM started on insulin pump therapy at SJHC 
between September 2008 and August 2011 identified via WebDR 
and DEC list of pump starts 
              DEC (224) 
 
               N = 119 
WebDR (229) 
  
   N = 124  
348 unique patient records 
180 patients who met inclusion criteria 
NOT INCLUDED (N=168) 
Pump start prior to Sept 2008                  N=129 
Pump start prior to being seen at SJHC      N=10 
Pump start prior to age 19       N=8 
No longer followed/inactive record             N=8 
Pump start after August 2011       N=3 
Pump start during pregnancy      N=3 
Pregnancy within 1 year of pump start      N=2 
Never started on pump        N=2 
Pump start prior to 2009 (date unknown) N=1 
Pump therapy duration <1 year      N=1 
Paper chart not available for review            N=1 
     
FINAL INSULIN PUMP THERAPY PATIENT SAMPLE 
N = 174  
EXCLUDED (N=6) 
 
No pre-pump A1C value available N=4 
No post-pump A1C value available           N=1 
Not able to be matched  
(no T1DM diagnosis date)                           N=1 
N = 105 
Figure 4 – Insulin Pump Therapy Cohort Selection 
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Table 4 – Comparison of Final Insulin Pump Therapy Cohort vs. Insulin Pump Therapy 
Patients Not Included/Excluded 
 
Variables Final IPT  
Cohort 
n=174 
IPT Patients not 
included/excluded 
n=174 
p-value 
Age (years) 45.0 ± 12.8 39.8 ± 13.2 <0.001† 
Duration of T1DM (years) 25.2 ± 13.1 23.5 ± 11.8* 0.205† 
Sex  (Male) – n (% ) 80 (46.0) 61 (35.1) 0.038‡ 
       
     IPT, insulin pump therapy; T1DM, type 1 diabetes mellitus 
     Data are mean values ± SD or number and frequency 
     
*
9 patients of those not included/excluded were missing data on duration of T1DM  
     Comparison between groups using 
†
two sample t-test or 
‡
Chi-square test  
 
 
 
  
                       
Figure 5 – Distribution of Age Differences Between Matched Pairs of Insulin Pump Therapy and Control Subjects
(%) 
84.5% 
4
3
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4.2 Baseline Cohort Characteristics  
The baseline demographic characteristics are shown in Table 5. Given that the duration 
of T1DM and current age were the matching variables, as expected these did not differ 
significantly between the IPT and control cohorts. The mean duration of T1DM of both 
cohorts was 25.2 ± 13.1 years. The mean current age was 45.0 ± 12.8 years for the IPT 
cohort and 45.3 ± 13.2 years for the control cohort (p=0.350). There was no significant 
difference in gender, city of residence, or average yearly household income between the 
cohorts (all p>0.05).  However, a significantly higher proportion of control subjects 
(17.2%, n=30) than IPT subjects (6.9%, n=12) had a private drug plan (p=0.006), and a 
significantly lower proportion of control subjects (91.4%, n=159) than IPT subjects 
(97.1%, n=169) were followed by an Endocrinologist for their T1DM (p=0.031).  
 
Table 5 – Baseline Demographic Characteristics of the Insulin Pump Therapy and 
Control Cohorts 
 
 IPT Cohort 
n=174 
Control Cohort 
n=174 
p-value 
Age (years)  45.0 ± 12.8 45.3 ± 13.2 0.350† 
Duration of T1DM (years)  25.2 ± 13.1 25.2 ± 13.1 N/A 
Gender (Male) – n (%) 80 (46.0) 97 (55.8) 0.100‡ 
Private Drug Plan - n (%) 12 (6.9) 30 (17.2) 0.006‡ 
City (London) - n (%) 80 (46.0) 90 (51.7) 0.358‡ 
Physician (Endocrinologist) – n (%) 169 (97.1) 159 (91.4) 0.031‡ 
Average Yearly Household Income 
(CAD) 
$70,922 ± $12,850 $70,528 ± $13,942 0.799† 
   
IPT, insulin pump therapy; T1DM, type 1 diabetes mellitus; N/A, not applicable  
       
Data are mean values ± SD or number and frequency  
Comparison between cohorts using 
†
paired t-test or 
‡
McNemar’s test  
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The baseline clinical characteristics of each cohort are shown in Table 6. There was no 
significant difference in baseline A1C between the IPT and control cohorts (IPT: 0.078 ± 
0.011 vs. control: 0.078 ± 0.013, p=0.586), nor any significant difference between the 
proportions of IPT and control subjects with an optimal (i.e. ≤ 0.070) baseline A1C (IPT: 
25.3%, n=44 vs. control: 24.7%, n=43, p=1.000). Similarly, there was no significant 
differences between the proportions of IPT and control subjects with a baseline A1C ≤ 
0.073 (IPT: 35.1%, n=61 vs. control: 34.5%, n=60) or ≤ 0.075 (IPT: 43.7%, n=76 vs. 
control: 43.7%, n=76) (both p=1.000). The cohorts also did not differ significantly in their 
baseline BMI, total daily insulin dose, or number of insulin injections per day.  
However, there was a significantly lower proportion of current smokers in the IPT cohort 
(4.0%, n=7) than the control cohort (19.0%, n=33) (p<0.001). Further, the proportion of 
subjects with at least one diabetes-related complication was significantly lower in the 
IPT cohort (34.5%, n=60) than the control cohort (44.8%, n=78) (p=0.044). Similarly, the 
proportion of subjects with at least one glycaemic-responsive complication was 
significantly lower in the IPT cohort (33.3%, n=58) than the control cohort (43.7%, n=76) 
(p=0.047). These differences in diabetes-related complications appeared to be mediated 
by a difference in the prevalence of neuropathy between the cohorts (IPT: 10.9%, n=19 
vs. control: 19.0%, n=33, p=0.034). The IPT cohort also had a significantly higher mean 
baseline number of CBG checks per day compared to the control cohort (IPT: 4.0 ± 0.8 
vs. control: 3.7 ± 0.9, p=0.003).  
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 Table 6 – Baseline Clinical Characteristics of the Insulin Pump Therapy and Control 
Cohorts 
 
 
IPT, insulin pump therapy; A1C; glycated hemoglobin; CVD, cerebrovascular disease; CAD, 
coronary artery disease; PVD, peripheral vascular disease; BMI, body mass index; kg, kilogram; 
m, meter; TDD, total daily insulin dose; CBG, capillary blood glucose  
 
Data are mean values ± SD or number and frequency  
Due to missing data, not all 174 pairs were compared for all variables  
 
*
Optimal A1C defined as ≤ 0.070 
§
Glycaemic-responsive complications include retinopathy, nephropathy and neuropathy 
Comparison between cohorts using 
†
paired t-test or 
‡
McNemar’s test 
 
 
 
IPT Cohort 
                               n 
Control Cohort 
                           n 
p-value 
Pairs 
included in 
analysis, n 
Baseline A1C 0.078 ± 0.011 
174 
 
0.078 ± 0.013 
174 
 
0.586
†
 
174 
 
% with optimal
*
 baseline A1C – n (%) 44 (25.3) 43 (24.7) 1.000
‡
 
Current smoking – n (%) 7 (4.0) 33 (19.0) <0.001
‡
 
At least 1 complication – n (%) 60 (34.5) 78 (44.8) 0.044
‡
 
At least 1 glycaemic-responsive
§ 
complication – n (%) 
58 (33.3) 76 (43.7) 0.047
‡
 
Complications – n (%)                   CVD 
CAD 
PVD 
Retinopathy 
Nephropathy 
Neuropathy 
0 (0) 2 (1.2) N/A 
6 (3.5) 6 (3.5) 1.000
‡
 
1 (0.6) 0 (0) N/A 
39 (22.4) 51 (29.3) 0.162
‡
 
25 (14.4) 37 (21.3) 0.111
‡
 
19 (10.9) 33 (19.0) 0.034
‡
 
Baseline BMI (kg/m2) 26.4 ± 4.7 156 27.3 ± 5.5 149 0.281
†
 135 
Baseline TDD (units) 52.2 ± 25.6 161 58.1 ± 33.7 170 0.101
†
 157 
Baseline # CBG/day 4.0 ± 0.8 163 3.7 ± 0.9 158 0.003
†
 148 
Baseline # insulin injections/day        4.2 ± 0.5 168 4.2 ± 0.7 168 0.794
†
 162 
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A large number of subjects in both cohorts were missing data on the use of CGMS and 
the number of adverse events at baseline. Only 2 IPT subjects documented use of CGMS, 
while data on CGMS use was missing for the other 172 IPT subjects and all 174 control 
subjects. For adverse events at baseline, in those with available data, there were no 
documented episodes of DKA at baseline in either cohort (number of subjects with data 
for DKA: n=36 IPT cohort, n=48 control cohort) but there were 17 episodes of severe 
hypoglycaemia in 125 IPT cohort subjects at baseline and 15 episodes of severe 
hypoglycaemia in 115 control cohort subjects at baseline. The corresponding baseline 
incidences for severe hypoglycaemia were not significantly different between cohorts: 
13.6 events per 100 patient-years in the IPT cohort and 13.0 events per 100 patient-
years in the control cohort (p=0.946 negative binomial regression).  
The pump therapy-related characteristics of the IPT cohort are shown in Table 7. The 
mean age at the start of IPT was 41.8 ± 12.7 years, and the mean duration of T1DM at 
the start of IPT was 22.0 ± 13.0 years. The majority (88.5%, n=154) of the IPT cohort used 
a Medtronic pump. The distribution of the timing of both ADP applications and ADP 
pump trial starts varied from 2008-2011 (though 2008 and 2011 were incomplete years). 
The mean wait time from referral to the SJHC DEC until the DEC appointment for the 
ADP process was 2.3 ± 2.4 months (wait time data available for only 69 subjects).
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Table 7 – Pump Therapy-Related Characteristics of the Insulin Pump Therapy Cohort 
 
 IPT Cohort 
n=174 
Age at Pump Start (years)  41.8 ± 12.7 
Duration of T1DM at Pump Start (years) 22.0 ± 13.0 
Brand of Pump – n (%) 
                                                                    Medtronic 
                                                                         Animas 
 
154 (88.5) 
20 (11.5) 
Year of ADP application – n (%) 
                                                                         2008* 
                                                                     2009   
                                                                     2010 
                                                                     2011* 
                                                                       Missing 
 
14 (8.1) 
83 (47.7) 
38 (21.8) 
21 (12.1) 
18 (10.3) 
Year of ADP Pump trial start – n (%) 
                                                                      2008* 
                                                                     2009 
                                                                     2010 
                                                                     2011* 
                                                                    Missing 
 
4 (2.3) 
54 (31.0) 
51 (29.3) 
36 (20.7) 
29 (16.7) 
        
        IPT, insulin pump therapy; T1DM, type 1 diabetes mellitus; ADP, Assistive Devices Program   
        Data are mean values ± standard deviation or number and frequency 
        
*
partial years – 2008 includes 4 months (September-December) and 2011 includes 8 months  
          (January-August)  
 
49 
 
 
4.3 Cohort Characteristics at Follow-Up 
The mean BMI and mean number of CBG per day in each year following IPT start (IPT 
cohort) or t=0 (control cohort) are shown in Figure 6A and B. The mean number of 
insulin injections per day in each year following t=0 for the control cohort is shown in 
Figure 7.  
The mean BMI of the IPT cohort in the IPT start year was 26.5 ± 4.7 kg/m2 (n=154), and 
at t=0 year in the control cohort was 27.5 ± 6.3 kg/m2 (n=142). The mean BMI of the IPT 
cohort at year 4 post-IPT start was 27.0 ± 4.4 kg/m2 (n=5), while the mean BMI of the 
control cohort at year 4 post-t=0 was 25.9 ± 4.2 kg/m2 (n=5) (Figure 6A). 
The mean number of CBG per day in the IPT cohort at IPT start year was 3.9 ± 0.5 
(n=157), and at t=0 year in the control cohort was 3.7 ± 1.0 (n=152). At year 4 post-IPT 
start/t=0, the mean number of CBG per day was 4.0 ± 0.0 in the IPT cohort (n=4) and 3.5 
± 1.0 in the control cohort (n=4) (Figure 6B). 
The mean number of insulin injections per day in the control cohort at t=0 year was 4.2 ± 
0.6 (n=167), while the mean number of insulin injections per day at year 4 post-t=0 was 
4.3 ± 0.5 (n=4) (Figure 7). 
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Figure 6 – Mean Body Mass Index and Mean Number of Capillary Blood Glucose 
Checks Per Day at Yearly Follow-Up for Insulin Pump Therapy and Control Cohorts
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         Error bars represent standard deviation 
         Year 0 is the t=0 year  
         Data were classified as per calendar year, and length of follow-up was variable, thus not all  
         subjects had data for each year (sample size at each year provided) 
 
Figure 7 – Mean Number of Insulin Injections Per Day at Yearly Follow-Up for Control 
Cohort 
 
 
4.4 Glycaemic Control Outcomes 
The timing of the follow-up A1C measurement varied by subject. The distribution of the 
timing of the follow-up A1C measurement for each cohort is shown in Figure 8. For both 
cohorts, the timing of the follow-up A1C measurements was normally distributed. The 
mean time for the follow-up A1C measurement was 11.7 ± 2.0 months post-IPT start 
(IPT cohort) and 11.4 ± 4.4 months post-t=0 date (control cohort); these were not 
significantly different (p=0.369 paired t-test).   
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Analysis 1 required that the follow-up A1C be between 10.5 – 13.5 months post-IPT 
start/post-t=0 date—if no A1C was measured in this window, the subject was excluded 
from the analysis. As seen in Figure 8, 81.0% (n=141) of IPT subjects and 52.9% (n=92) of 
control subjects had follow-up A1C measurements between 10.5 – 13.5 months.   
Analysis 2 required that the follow-up A1C be between 10.5 – 13.5 months post-IPT 
start/post-t=0 date. However, if no A1C was measured in this window, but an A1C 
measurement between 0 – 10.5 months post-IPT start/post-t=0 date was available, the 
subject was included and the follow-up A1C was imputed using LOCF.  If no A1C 
measurement between 0 – 13.5 months post-IPT start/t=0 date was available for a 
subject, they were excluded from the analysis.  As seen in Figure 8, 91.4% (n=159) of IPT 
subjects and 85.1% (n=148) of control subjects had follow-up A1C measurements 
between 0 – 13.5 months. 
4.4.1 Change in A1C 
The mean baseline A1C, mean follow-up A1C, and mean change in A1C from baseline to 
follow-up for each cohort are shown in Table 8.  
Insulin Pump Therapy Cohort 
The mean baseline A1C in the IPT cohort was 0.078 ± 0.011. In Analysis 1, the mean 
follow-up A1C was 0.075 ± 0.009, for a mean change in A1C of -0.002 ± 0.009. In Analysis 
2, the mean follow-up A1C was 0.075 ± 0.010, for a mean change in A1C of -0.002 ± 
0.009. In both analyses, the change in A1C from baseline to follow-up was statistically 
significant (Analysis 1, p=0.009; Analysis 2, p=0.002). 
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Table 8 – Mean A1C at Baseline and Follow-Up, and Mean Change in A1C for Insulin 
Pump Therapy and Control Cohorts 
 
 
A1C, glycated hemoglobin; IPT, insulin pump therapy 
 
Data are presented as mean values ± standard deviation 
*Comparison of baseline vs. follow-up A1C using paired t-test 
Control Cohort 
The mean baseline A1C in the control cohort was 0.078 ± 0.013. In Analysis 1, the mean 
follow-up A1C was 0.078 ± 0.014, for a mean change in A1C of 0.000 ± 0.010. In Analysis 
2, the mean follow-up A1C was 0.080 ± 0.013, for a mean change in A1C of 0.001 ± 
0.010. In both analyses, the change in A1C from baseline to follow-up was not 
statistically significant (Analysis 1, p=0.952; Analysis 2, p=0.487). 
4.4.2 Paired Difference in A1C Change Score 
The mean paired difference in A1C change scores between matched pairs of IPT and 
control subjects is shown in Table 9.  In Analysis 1, the mean paired difference in the A1C 
change score was -0.003 ± 0.015, which was not statistically significant (p=0.126). 
However, in Analysis 2, the mean paired difference in the A1C change score was -0.003 ± 
0.015, which was statistically significant (p=0.041). 
 
Cohort Analysis 
Baseline A1C 
n=174 
Follow-Up A1C 
                           n 
Change in A1C 
(Follow-Up – Baseline) 
p-value* 
 
IPT 
(1) 
0.078 ± 0.011 
0.075 ± 0.009 141 -0.002 ± 0.009 0.009 
(2) 0.075 ± 0.010 159 -0.002 ± 0.009 0.002 
 
Control 
(1) 
0.078 ± 0.013 
0.078 ± 0.014 92 0.000 ± 0.010 0.952 
(2) 0.080 ± 0.013 148 0.001 ± 0.010 0.487 
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Table 9 – Mean Paired Difference in A1C Change Score for Matched Pairs of Insulin 
Pump Therapy and Control Subjects 
 
  
A1C, glycated hemoglobin; IPT, insulin pump therapy 
 
Data are presented as mean values ± standard deviation 
*Comparison of A1C change score for each matched IPT-control pair using paired t-test 
 
4.4.3 Optimal A1C at Baseline and at Follow-Up 
The proportions of subjects with an optimal A1C at baseline compared to follow-up in 
each cohort are shown in Table 10. “Optimal” A1C was defined as an A1C ≤ 0.070.  
Insulin Pump Therapy Cohort 
In Analysis 1, the proportion of IPT subjects with an optimal A1C at baseline was 27.0% 
(n=38), and at follow-up was 33.3% (n=47). These were not significantly different 
(p=0.163). In Analysis 2, the proportion of IPT subjects with an optimal A1C at baseline 
was 25.8% (n=41) and at follow-up was 32.1% (n=51), and these were also not 
significantly different (p=0.143). 
Control Cohort 
In Analysis 1, the proportion of control subjects with an optimal A1C at baseline and at 
follow-up were 22.8% (n=21) and 26.1% (n=24), respectively. These were not 
significantly different (p=0.607). In Analysis 2, the proportions of control subjects with 
an optimal A1C at baseline and follow-up were the same—both were 23.0% (n=34).  
 
  
Analysis 
Paired Difference in A1C Change Scores 
(IPT Change in A1C – Control Change in A1C) 
p-value* 
Pairs included in 
analysis, n 
(1) -0.003 ± 0.015 0.126 74 
(2) -0.003 ± 0.015 0.041 133 
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Table 10 – Difference in Proportion of Subjects with an Optimal A1C at Baseline vs. at 
Follow-Up in Insulin Pump Therapy and Control Cohorts 
     
 
A1C, glycated hemoglobin; IPT, insulin pump therapy 
 
Data are presented as number (percentage) 
 *Comparison of proportion at baseline vs. at follow-up using McNemar’s test 
 
However, given that the target “optimal” level of A1C should be individualized according 
to patient-specific factors, we repeated the analyses using pre-specified higher, but still 
clinically relevant, threshold levels (A1C ≤ 0.073 and ≤ 0.075), and these results are 
shown in Tables 11A and 11B.  In the IPT cohort in both Analysis 1 and 2, there was a 
significantly higher proportion of subjects with an A1C ≤ 0.073 at follow-up (Analysis 1: 
46.1%, n=65; Analysis 2: 45.3%, n=72) than at baseline (Analysis 1: 36.2%, n=51; Analysis 
2: 35.2%, n=56) (Analysis 1: p=0.034, Analysis 2: p=0.023). Similarly, in both Analysis 1 
and 2, there was a significantly higher proportion of subjects with an A1C ≤ 0.075 at 
follow-up (Analysis 1: 55.3%, n=78; Analysis 2: 55.4%, n=88) than at baseline (Analysis 1: 
44.0%, n=62; Analysis 2: 43.4%, n=69) (Analysis 1: p=0.014, Analysis 2, p=0.005). 
 
 
 
 
Cohort Analysis 
Optimal A1C at 
Baseline 
Optimal A1C at 
Follow-Up 
p-value* 
Pairs included 
in analysis, n 
 
IPT 
(1) 38 (27.0) 47 (33.3) 0.163 141 
(2) 41 (25.8) 51 (32.1) 0.143 159 
 
Control 
(1) 21 (22.8) 24 (26.1) 0.607 92 
(2) 34 (23.0) 34 (23.0) 1.000 148 
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Table 11 – Difference in the Proportion of Subjects with an A1C ≤ 0.073 and ≤ 0.075 at 
Baseline vs. at Follow-Up in Insulin Pump Therapy and Control Cohorts 
 
A) 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
A1C, glycated hemoglobin; IPT, insulin pump therapy 
 
Data are presented as number (percentages) 
*Comparison of proportion of subjects at baseline vs. at follow-up using McNemar’s test 
 
However, this pattern was not seen within the control cohort—there was no significant 
difference in the proportions of control subjects with an A1C ≤ 0.073 or an A1C ≤ 0.075 
at follow-up compared to at baseline in either Analysis 1 or 2.  
Cohort Analysis 
A1C ≤ 0.073 at 
Baseline 
A1C ≤ 0.073 at  
Follow-Up 
p-value
*
 
Pairs included in 
analysis, n 
 
IPT 
(1) 51 (36.2) 65 (46.1) 0.034 141 
(2) 56 (35.2) 72 (45.3) 0.023 159 
 
Control 
(1) 33 (35.9) 36 (39.1) 0.581 92 
(2) 50 (33.8) 48 (32.4) 0.839 148 
Cohort Analysis 
A1C ≤ 0.075 
at Baseline 
A1C ≤ 0.075 
At Follow-Up 
p-value
*
 
Pairs included in 
analysis, n 
      
IPT 
(1) 62 (44.0) 78 (55.3) 0.014 141 
(2) 69 (43.4) 88 (55.4) 0.005 159 
 
Control 
(1) 44 (47.8) 46 (50.0) 0.815 92 
(2) 63 (42.3) 66 (44.6) 0.701 148 
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The proportions of subjects with an optimal A1C at follow-up (i.e. ≤ 0.070) were 
compared between the IPT and control cohorts, and the results are shown in Table 12. 
In Analysis 1, there were no significant differences between cohorts in the proportions 
of subjects with an optimal follow-up A1C. However, in Analysis 2, the IPT cohort had a 
significantly higher proportion of subjects with a follow-up A1C ≤ 0.070 (33.8%, n=45) 
compared to the control cohort (21.8%, n=29) (p=0.044). 
 
 Table 12 – Difference in the Proportion of Subjects with Follow-Up A1C ≤ 0.070 in 
Matched Pairs of Insulin Pump Therapy and Control Subjects 
 
      
 
 
 
 
 
A1C, glycated hemoglobin; IPT, insulin pump therapy 
 
Data are presented as number (percentage) 
*
Comparison of proportion of subjects in IPT vs. control cohorts using McNemar’s test 
 
 
Analysis IPT Control p-value* 
Pairs included in 
analysis, n 
(1) 23 (31.1) 18 (24.3) 0.487 74 
(2) 45 (33.8) 29 (21.8) 0.044 133 
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4.5 Adverse Events 
The number of episodes of DKA and severe hypoglycaemia per calendar year were 
collected for each subject in the 1 year prior to IPT start/t=0 year (baseline), the year of 
IPT start/t=0, and yearly thereafter. Due to varying length of follow-up and missing data, 
not all subjects had adverse event data for each follow-up year.  There were no DKA 
episodes reported for either cohort at any follow-up year (number of subjects with data 
on DKA: IPT start/t=0 year n=23 (IPT), n=49 (control); year 1 n=30 (IPT), n=46 (control); 
year 2 n=18 (IPT), n=37 (control); year 3 n=10 (IPT), n=23 (control), year 4 n=3 (IPT), n=2 
(control)). The incidence of severe hypoglycaemic events at baseline and after 1 year 
post-IPT start/t=0 is shown in Figure 9. As shown previously, there was no significant 
difference in the incidence of severe hypoglycaemia between cohorts in the 1 year prior 
to IPT start/t=0 (baseline). However, after 1 year post-IPT start/t=0, the IPT cohort had a 
significantly lower incidence of severe hypoglycaemia (2 events in 149 patients, for an 
incidence of 1.3 events per 100 patient-years) compared to the control cohort (14 
events in 124 patients, for an incidence of 11.3 events per 100 patient years) (p=0.016). 
There was no significant difference in the incidence of severe hypoglycaemia between 
cohorts in year 2 (IPT: 2.9 per 100 patient-years vs. control: 3.8 per 100 patient-years, 
p=0.743) or year 3 (IPT: 2.6 per 100 patient-years vs. control: 7.3 per 100 patient years, 
p=0.376) post-IPT start/t=0. No episodes of severe hypoglycaemia were reported in 
either cohort in year 4 post-IPT start/t=0.  
 
  
IPT, insulin pump therapy 
 
Data were classified as per calendar ye
subjects had data for each year (sample size at each year provided)
*p=0.016 IPT vs. control, negative binomial regression
Figure 9 – Incidence of Severe Hypoglycaemic Events 
(baseline) and After 1 Year
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4.6 Missing Data – Follow-Up A1C Values 
The proportion of subjects with missing follow-up A1C values in each analysis for each 
cohort was compared. In Analysis 1, 82 control subjects (47.1%) and 33 IPT subjects 
(19.0%) were missing follow-up A1C values in the pre-specified time window, and the 
proportion in the control cohort was significantly higher than the IPT cohort (p<0.001). 
However, in Analysis 2, after using LOCF to impute missing values in 56 (32.2%) control 
and 18 (10.3%) IPT subjects, there was no significant difference between cohorts in the 
proportion of subjects missing follow-up A1C values (control: n=26, 14.9% vs. IPT: n=15, 
8.6%, p=0.117).  
The baseline characteristics between those with missing vs. non-missing follow-up A1C 
values were compared for each cohort (Appendices J and K). 
Insulin Pump Therapy Cohort 
In Analysis 1, there were 33 IPT subjects with missing follow-up A1C data. Compared to 
IPT subjects without missing A1C data, those with missing A1C data had a significantly 
lower mean baseline BMI (25.2 ± 3.6 kg/m2, n = 30 vs. 26.8 ± 4.9 kg/m2, n=126, p=0.049) 
and lower mean baseline TDD (43.8 ± 18.4 units, n=30 vs. 54.1 ± 26.6 units, n=131, 
p=0.014). There were no differences in any other baseline characteristics between these 
two groups (Appendix J). 
In Analysis 2, there were 15 IPT subjects with missing follow-up A1C data. There were no 
significant differences in baseline characteristics between these subjects and the 159 IPT 
subjects who were not missing A1C data (Appendix J). 
Control Cohort 
In Analysis 1, there were 82 control subjects with missing follow-up A1C data. Compared 
to control subjects without missing A1C data, those with missing A1C data had a 
significantly lower mean baseline TDD (52.8 ± 25.4 units, n=81 vs. 62.9 ± 39.4 units, 
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n=89; p=0.048) and were less likely to have a private drug plan (11.0%, n=9 vs. 22.8%, 
n=21; p=0.039). There were no differences in any other baseline characteristic between 
these two groups (Appendix K).  
In Analysis 2, there were 26 control subjects with missing follow-up A1C data. There 
were no significant differences in baseline characteristics between these subjects and 
the 148 control subjects who were no missing A1C data (Appendix K).  
 
4.7 Sensitivity Analyses 
Effect of Wider Age Differences in Age-Matched Pairs 
Of the 174 IPT-control pairs, 27 (15.5%) were not matched within a ± 5 year age 
difference. A sensitivity analysis including only the 147 pairs that were matched within 
this window of age differences showed similar results as presented above—a significant 
change in A1C was seen from baseline to follow-up in the IPT cohort but not in the 
control cohort (IPT: -0.002 ± 0.010, p=0.006 (Analysis 1); -0.003 ± 0.010, p=0.001 
(Analysis 2); Control: 0.000 ± 0.011, p=0.967 (Analysis 1); 0.001 ± 0.011, p=0.369 
(Analysis 2)) and a significant paired difference in change in A1C for matched IPT-control 
pairs was seen in Analysis 2 only (Analysis 1: -0.003 ± 0.016, p=0.119; Analysis 2: -0.004 ± 
0.016, p=0.013). 
Effect of Imputing Follow-Up A1C values from <6 Months Post-IPT Start/t=0 
In Analysis 2, 18 (10.3%) IPT subjects and 56 (32.2%) control subjects had follow-up A1C 
values imputed using LOCF of values measured between 0-10 months post-IPT start/t=0. 
A sensitivity analysis imputing the follow-up values of only the 16 (9.2%) IPT subjects and 
40 (26.4%) control subjects whose follow-up A1C were measured between 6-10 months 
post-IPT start/t=0 showed similar results as presented above—a significant change in 
A1C from baseline to follow-up was seen in the IPT cohort but not the control cohort 
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(IPT: -0.002 ± 0.010, p=0.002; Control: 0.000 ± 0.011, p=0.616) and a significant  paired 
difference in change in A1C for matched IPT-control pairs was seen (-0.003 ± 0.015, 
p=0.049). 
 
4.8 Subgroup Analysis 
The mean baseline and follow-up A1C, and the mean change in A1C from baseline to 
follow-up for both cohorts stratified by baseline A1C are shown in Tables 13 and 14. 
Three subgroups were defined according to the following A1C levels: ≤ 0.070, 0.071 to 
0.080, and ≥ 0.081. The baseline TDD was also compared between subgroups. 
Insulin Pump Therapy Cohort 
Analysis 1:  
In the subgroup with baseline A1C ≤ 0.070, the A1C significantly increased from baseline 
to follow-up (mean baseline A1C 0.065 ± 0.004 and mean follow-up A1C 0.069 ± 0.007) 
for a mean A1C change of 0.004 ± 0.008 (p<0.01). In the subgroup with baseline A1C ≥ 
0.081, the A1C significantly decreased from baseline to follow-up (mean baseline A1C 
0.088 ± 0.009 and mean follow-up A1C 0.081 ± 0.009) for a mean A1C change of -0.007 ± 
0.009 (p<0.0001). However, for the subgroup with baseline A1C 0.071 to 0.080, there 
was no significant change in A1C from baseline to follow-up (Table 13A).  
Analysis 2: 
A similar pattern was seen for Analysis 2. In the subgroup with baseline A1C ≤ 0.070, the 
A1C significantly increased from a mean baseline A1C of 0.065 ± 0.004 to a mean follow-
up A1C of 0.069 ± 0.007, for a mean A1C change of 0.004 ± 0.008 (p=0.004). In the 
subgroup with baseline A1C ≥ 0.081, the A1C significantly decreased from a mean 
baseline A1C of 0.088 ± 0.009 to a mean follow-up A1C of 0.081 ± 0.010, for a mean A1C 
change of -0.007 ± 0.009 (p<0.0001).  
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Table 13 – Subgroup Analysis: Mean A1C at Baseline and Follow-Up, Mean Change in A1C and Mean Baseline Total Daily Insulin 
Dose for Insulin Pump Therapy Cohort - Stratified by Baseline A1C 
A) 
 
B) 
 
Subgroup 
Baseline Total Daily Dose (units) 
                                          n 
p-value
†
 
≤ 0.070 46.7 ± 24.1 42 
0.229 0.071 – 0.080 52.8 ± 25.5 60 
≥ 0.081 55.5 ± 26.5 59 
 
A1C, glycated hemoglobin 
Data are presented as mean ± standard deviation 
*Comparison of baseline and follow-up A1C values within each subgroup by paired t-test 
†Comparison of baseline total daily dose between subgroups by one-way ANOVA 
 
Insulin Pump Therapy Cohort 
Analysis Subgroup 
Baseline A1C 
                              n 
Follow-Up A1C 
                               n 
Change in A1C  
(Follow-Up – Baseline) 
p-value
*
 
Pairs included 
in analysis, n 
(1) 
≤ 0.070 0.065 ± 0.004 44 0.069 ± 0.007 38  0.004 ± 0.008 <0.01 38 
0.071 – 0.080 0.076 ± 0.003 66 0.074 ± 0.008 49 -0.001 ± 0.008 0.249 49 
≥ 0.081 0.088 ± 0.009 64 0.081 ± 0.009 54 -0.007 ± 0.009 <0.0001 54 
  
(2) 
≤ 0.070 0.065 ± 0.004 44 0.069 ± 0.007 41   0.004 ± 0.008 0.004 41 
0.071 – 0.080 0.076 ± 0.003 66 0.074 ± 0.008 58 -0.002 ± 0.008 0.148 58 
≥ 0.081 0.088 ± 0.009 64 0.081 ± 0.010 60 -0.007 ± 0.009 <0.0001 60 
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Table 14 - Subgroup Analysis: Mean A1C at Baseline and Follow-Up, Mean Change in A1C and Mean Baseline Total Daily Insulin 
Dose for Control Cohort - Stratified by Baseline A1C 
A) 
 
B)  
Subgroup 
Baseline Total Daily Dose (units) 
                                          n 
p-value
†
 
≤ 0.070 44.3 ± 28.2 43  
0.019
‡
 0.071 – 0.080 47.8 ± 24.4 66 
≥ 0.081 59.2 ± 33.4 62 
 
A1C, glycated hemoglobin 
Data are presented as mean ± standard deviation 
*Comparison of baseline and follow-up A1C values within each subgroup by paired t-test 
†Comparison of baseline total daily dose between subgroups by one-way ANOVA 
‡As per the Tukey-Kramer test, the mean baseline total daily dose was significantly different between the subgroups with baseline A1C ≤0.070 
and ≥0.081 (p<0.05) 
Control Cohort 
Analysis Subgroup 
Baseline A1C 
                              n 
Follow-Up A1C 
                                  n 
Change in A1C  
(Follow-Up – Baseline) 
p-value
*
 
Pairs included 
in analysis, n 
(1) 
≤ 0.070 0.064 ± 0.004 43 0.067 ± 0.007 21  0.003 ± 0.006 0.034 21 
0.071 – 0.080 0.076 ± 0.003 68 0.076 ± 0.007 40  0.001 ± 0.006 0.301 40 
≥ 0.081 0.091 ± 0.011 63 0.089 ± 0.017 31 -0.003 ± 0.016 0.310 31 
  
(2) 
≤ 0.070 0.064 ± 0.004 43 0.068 ± 0.008 34   0.004 ± 0.006 0.001 34 
0.071 – 0.080 0.076 ± 0.003 68 0.077 ± 0.007 58   0.001 ± 0.005 0.094 58 
≥ 0.081 0.091 ± 0.011 63 0.090 ± 0.014 56 -0.002 ± 0.015 0.346 56 
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However, in the subgroup with baseline A1C 0.071 to 0.080, there was again no 
significant change in A1C from baseline to follow-up (Table 13A). There was no 
significant difference in baseline TDD between subgroups (Table 13B). 
Control Cohort 
Analysis 1:  
In the subgroup with baseline A1C ≤ 0.070, the A1C significantly increased from baseline 
to follow-up (mean baseline A1C 0.064 ± 0.004 and mean follow-up A1C 0.067 ± 0.007) 
for a mean A1C change of 0.003 ± 0.006 (p=0.034). However, there was no significant 
change in A1C from baseline to follow-up in either the subgroup with baseline A1C 0.071 
to 0.080 or the subgroup with baseline A1C ≥ 0.081 (Table 14A).  
Analysis 2: 
Similarly, in Analysis 2, only the subgroup with baseline A1C ≤ 0.070 showed a significant 
change in A1C from baseline to follow-up (mean baseline A1C 0.064 ± 0.004 and mean 
follow-up A1C 0.068 ± 0.008), for a mean A1C change of 0.004 ± 0.006 (p=0.001). The 
subgroups with baseline A1C 0.071 to 0.080 and baseline A1C ≥ 0.081 did not show any 
significant change in A1C from baseline to follow-up (Table 14A).  
However, there was a significant difference in the baseline TDD among the 3 subgroups 
in the control cohort (p=0.019) (Table 14B). The subgroup with a baseline A1C ≤ 0.070 
had a significantly lower baseline TDD than the subgroup with a baseline A1C ≥ 0.081 
(p<0.05). 
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4.9 Summary of Results 
This retrospective cohort study ascertained a group of adult IPT users funded by the 
MOHLTC ADP, and compared their glycaemic control at approximately 1 year after IPT 
start to a cohort of control subjects matched by T1DM duration and age.  Data on 
adverse outcomes at baseline and follow-up (yearly up to 4 years post-IPT start/t=0) 
were also collected.   
Subjects in the IPT cohort had a significant decrease in A1C from baseline to 1 year 
follow-up of 0.002 (or 0.2%), while the A1C level in the control cohort did not change. In 
the matched analysis, the mean paired difference in A1C change score between the IPT 
and control cohort subjects was -0.003, i.e. the mean improvement (decrease) in A1C 
was 0.003 (or 0.3%) more in the IPT cohort than in the control cohort.  Subjects in the 
IPT cohort were more likely to have an optimal A1C at follow-up compared to those in 
the control cohort. 
No subjects in either cohort had any episodes of DKA at baseline or at yearly follow-up. 
The baseline incidence of severe hypoglycaemic events was similar in both cohorts, but 
after 1 year post-IPT start/t=0, the IPT cohort had a significantly lower incidence of 
severe hypoglycaemia compared to the control cohort. 
Exploratory subgroup analyses suggested that the effect of IPT use on the change in A1C 
differed according to baseline A1C where an improvement in A1C was seen in IPT 
subjects with baseline A1C levels ≥ 0.081, but a worsening in A1C was seen in IPT 
subjects with baseline A1C levels ≤ 0.070. No change was seen in those with baseline 
A1C levels 0.071 to 0.080.
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Chapter 5: Discussion 
5.1 Introduction 
Insulin pump therapy is becoming an increasingly utilized method of insulin 
administration in T1DM, and as of September 2013, the provincial government funding 
program subsidizing its use in adults in Ontario has been in place for 5 years. In mid-
2013, Alberta implemented an IPT funding program for residents of all ages, but 
otherwise, no other province in Canada provides financial support for IPT in adults with 
T1DM. 
There are no Canadian studies that have examined the impact of a provincial funding 
program for IPT in adults. Despite RCT evidence3-11 showing that IPT causes a small but 
significant improvement in glycaemic control, there is limited “real-world” evidence for 
the benefits of IPT on glycaemic control and adverse outcomes.  Prior observational 
studies,61-79 primarily in Europe, have been performed in small cohorts of adults with 
T1DM, but the majority of the studies did not have a control group, and most were in 
subjects with poor glycaemic control at baseline (i.e. baseline A1C values ≥ 0.080). 
Duration of IPT also varied widely between studies.61-79 
The objective of our study was to compare glycaemic control and adverse outcomes at 1 
year between a cohort of adult IPT users funded by the ADP and a control cohort, 
matched by age and T1DM duration in order to determine the impact of ADP-funded IPT 
in adults with T1DM in Ontario under “real-world” conditions. 
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5.2 Summary of Key Findings & Comparison with Previous Research 
5.2.1 Characterization of Insulin Pump Therapy Cohort 
The IPT cohort included 174 adults with a mean current age of 45.0 years (mean age at 
IPT start 41.8 years), mean current duration of T1DM of 25.2 years (mean duration at IPT 
start 22.0 years), and approximately equal numbers of males and females (80/94). They 
were overweight, with a mean BMI of 26.4 kg/m2, and very few (4%) were current 
smokers. Almost all (97.1%) were followed by an Endocrinologist, and slightly less than 
half (46%) lived in London. Their average yearly household income was $70,922, and 
very few (6.9%) had access to private drug plan coverage. The subjects had fairly good 
glycaemic control prior to initiating IPT with a mean baseline A1C of 0.078, and with 
25.3% of the cohort having a baseline A1C ≤ 0.070. Approximately one third had at least 
1 glycaemic-responsive complication (i.e. retinopathy, nephropathy or neuropathy) at 
baseline.  
The age and duration of T1DM of published observational cohorts of IPT users have 
varied. In general, the mean age and duration of T1DM at the time of IPT start in our IPT 
cohort (mean age 41.8 years, mean duration 22 years) was similar to that of IPT users in 
previous studies (mean age range 29 to 50.5 years, mean duration range 9.3-29 years).61-
79  
Of note, the duration of IPT use in previous observational studies was markedly different 
compared to our cohort. We characterized our IPT cohort from 1 year pre-IPT start until 
up to 4 years post-IPT start, though length of follow-up varied by subject based on year 
of IPT start (the mean available follow-up was 2.2 ± 0.8 years post-IPT start). To assess 
the change in glycaemic control while on IPT, we specifically examined the time period 
between 1 year pre- and 1 year post-IPT start. In previous studies61-79, the mean 
duration of IPT use ranged from 6 months to 13.1 years.   
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Furthermore, the cohorts of IPT users in previous observational studies61-79 had poorer 
glycaemic control at baseline compared to our IPT cohort—the mean baseline A1C of 
the IPT cohorts in the previous 19 studies was 0.085 (range 0.077-0.106), whereas our 
IPT cohort had fairly good glycaemic control at baseline (mean baseline A1C 0.078).  
5.2.2 Comparison of Insulin Pump Therapy and Control Cohorts 
The matched control cohort in our study included 174 adults who had similar baseline 
characteristics to the IPT subjects with some exceptions: fewer control subjects were 
followed by an Endocrinologist, more control subjects had private drug plan coverage, 
more control subjects were current smokers, and more control subjects had at least 1 
glycaemic-responsive complication (specifically neuropathy). The control cohort also 
performed a lower mean number of CBG checks per day at baseline.  
Taken together, except for the difference in private drug plan coverage, these baseline 
clinical differences between the control and IPT cohorts suggest that our control cohort 
was less invested in their health and T1DM self-care relative to our IPT cohort. It is 
interesting to note that, despite these differences, there was no difference in baseline 
glycaemic control between the IPT and control cohorts, with the same mean baseline 
A1C of 0.078 and a similar proportion (24.7%) with a baseline A1C ≤ 0.070. 
5.2.3 Glycaemic Control Outcomes 
Change in A1C from Baseline to Follow-Up 
At approximately 1 year post-IPT start, our IPT subjects had a significant decrease in A1C 
compared to baseline. The mean follow-up A1C in the IPT cohort was 0.075, which, 
while still suboptimal, represented a mean change in A1C of -0.002 from baseline in the 
IPT users (Analysis 1 and 2). At the same time, a similar decrease in A1C from baseline 
was not seen in our control subjects—their mean follow-up A1C ranged from 0.078 
(Analysis 1) to 0.080 (Analysis 2) which yielded a statistically and clinically non-significant 
mean change in A1C over 1 year of 0 to +0.001 from baseline.  
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Of the prior 19 observational studies evaluating the association between IPT and 
glycaemic control, 18 also showed a significant decrease in A1C with IPT use.61,62,64-79 
Four studies67,77-79 also reported a mean change in A1C from baseline to follow-up in IPT 
users, and showed slightly greater changes in A1C (range -0.0054 to -0.0115) as 
compared to our study. However, these studies defined their follow-up A1C differently 
than our study. Two of these studies77,78 also examined the change in A1C in a control 
group of non-IPT users. A summary comparing our results with the results of those 
studies reporting changes in A1C in the IPT group from baseline to follow-up and the 
difference in change in A1C between the IPT and control groups is shown in Table 15. 
 
Table 15 – Comparison of Results: Current Study and Prior Studies Reporting Change in 
A1C from Baseline to Follow-Up in Patients on Insulin Pump Therapy and Difference in 
Change in A1C Between Insulin Pump Therapy and Control Group 
 
Author 
(Year) 
Country  
(Data 
Source) 
Change in A1C from  
Baseline to Follow-up  
              (mean ± SD)                     n    
Timing of 
Follow-Up 
Difference between 
groups for change in 
A1C at Follow-up 
(mean ± SD) 
Liu 
(current 
study) 
Canada 
(3
o
 care 
centre) 
        IPT:     -0.002 ± 0.009           159 
Control:      0.001 ± 0.010           148 
1 year 
-0.003 ± 0.015 
(unadjusted 
paired difference, 
n=133 pairs) 
Carlsson
77
 
(2013) 
Sweden  
(EMR 
from 10 
clinics) 
 
IPT:     -0.0054 ± 0.0111       260 
Control:    -0.0003 ± 0.0086    2,213 
 
1 year 
   -0.0051 (unadjusted) 
   -0.0042 (adjusted) 
Cohen
78
 
(2013) 
Australia 
(3
o
 care 
centre) 
 
IPT:      -0.006                        102 
Control:      -0.001                        105 
 
1 year not reported  
Grant
79
 
(2013) 
United 
Kingdom 
(3
o
 care 
centre) 
 
IPT:      -0.010                        171 
           (no control group)   
 
6-12 
months 
N/A  
Lepore
67
 
(2005) 
Italy 
(3
o
 care 
centre) 
 
IPT:     -0.0115 ± 0.0084         82 
           (no control group)   
 
3 months  
 
N/A 
 
A1C, glycated hemoglobin; SD, standard deviation; IPT, insulin pump therapy; 3o, tertiary; EMR, 
electronic medical record; N/A, not applicable 
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 Carlsson et al.77 performed a retrospective cohort study in 272 subjects on IPT, 
measuring A1C at 1, 2 and 5 years of IPT use (the primary outcome was at 5 years). The 
mean change in A1C at 1 year in the IPT subjects was -0.0054, which was statistically 
significant.  For their primary outcome determination at 5 years, they used a large time 
window (5 years ± 6 months) for A1C measurement. As well, they defined A1C at 1 year 
as the first A1C value after 1 year, but did not specify the time window for 
measurement, making it unclear whether the 1 year value also was subject to the same 
large time window. In our study, our pre-specified window for follow-up A1C was 
relatively narrow (12 ± 1.5 months); this difference may partly explain why we observed 
a smaller mean change in A1C in our IPT cohort. Carlsson et al.77 also studied a matched 
control group of non-IPT users (matched by the IPT start date ± 182 days), with an 
average of 9 matched controls per IPT user and a total control group of 2437 subjects. 
Similar to what we observed in our control cohort, their control group did not have a 
significant change in A1C from baseline to 1 year (mean change -0.00033).  
Grant et al.79 retrospectively examined the impact of mental health problems on 
glycaemic control in 350 patients with T1DM on IPT. In the subgroup of IPT users 
without a history of mental health problems (n=171), the mean change in A1C from 
baseline to follow-up was -0.010, which was statistically significant. However, in this 
study, the time window for the follow-up A1C used for analysis was again relatively large 
being between 6-12 months post-IPT start. This difference may explain why we observed 
a smaller mean change in A1C. 
Cohen et al.78 performed a retrospective cohort study of 126 subjects newly started on 
IPT, and examined the change in A1C from baseline at 6 and 12 months, and then yearly 
from 2 until 5 years. The peak A1C reduction in the IPT group was -0.0064 at 6 months, 
with a statistically significant reduction of -0.0060 persisting at 1 year. However, the A1C 
values used in their analyses were the means of all A1C measurements in that time 
period (i.e. in the first 6 months, 12 months, and the mean for each subsequent year), 
which may contribute to the greater change in A1C as compared to what we saw in our 
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study.  In addition, unlike our study, the control cohort in Cohen et al. had a significant 
reduction in A1C of -0.0015 (at 6 months), but their control subjects participated in a 
structured 5 week education program (including 2.5 hour group meetings per week), 
similar to the DAFNE (Dose Adjustment For Normal Eating) program.89 This education 
program may explain why the control subjects in their study experienced a small but 
significant change in A1C at 6 months. However, at 1 year, the change in A1C in their 
control group was not significant.  
Lepore et al.67 conducted a retrospective cohort study in 82 subjects on IPT in which 
they examined A1C values which were measured every 3 months while subjects were on 
IPT (with mean IPT duration 31.9 ± 14.5 months). They showed a significant mean 
change in A1C of -0.0115 over this time, but, as in Cohen et al.,,78 the follow-up A1C 
value used in the analysis was the mean of all follow-up A1C measurements. Thus, their 
longer duration of follow-up with multiple A1C determinations may have allowed for 
detection of a greater change in A1C.  
In the current study, it was felt that the use of a single A1C value measured within the 
defined follow-up period was a more clinically relevant outcome measure, as opposed to 
the mean of all A1C values measured within that time. Using a mean of all measured 
A1C values may provide a broad reflection of the overall glycemic control in a time 
period, but it may not clearly illustrate the magnitude of change in A1C. For example, in 
2 subjects both with baseline A1C values of 0.080 and each with 2 subsequent follow-up 
A1C values—subject one with follow-up values of 0.090 then 0.070, and subject two 
with follow-up values of 0.100 then 0.060 —their mean follow-up A1C would be the 
same (0.080), giving a 0% change compared to baseline for both subjects, when in 
actuality both had a significant improvement in A1C compared to baseline, as per their 
second follow-up A1C values of 0.070 and 0.060, respectively.    
One study63 did not demonstrate a significant decrease in A1C from baseline to follow-
up in IPT users. Bode et al. performed a prospective cohort study in which 55 patients 
with T1DM with severe recurrent hypoglycaemia and/or suboptimal glycaemic control 
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(A1C ≥ 0.080) after ≥ 12 months of an intensive therapy program on an MDI regimen 
were crossed-over to IPT and followed for at least 12 more months.63 No significant 
change in A1C was observed from baseline on MDI to follow-up on IPT.  However, due to 
the intensive therapy program that was offered while on both MDI or IPT (including 
quarterly routine visits, 24-hour access to telephone support, and close phone and fax 
contact throughout), the glycaemic control of the subjects was fairly good at baseline on 
MDI (mean A1C 0.077 ± 0.015). Given that Bode et al. included subjects with recurrent 
severe hypoglycaemia, this may have limited the subjects’ ability to safely further 
tighten their glycaemic control on IPT.  The baseline incidence of severe hypoglycaemia 
on MDI in Bode et al. was high (138 events per 100 patient-years), which is 10-fold 
higher than the baseline incidence of severe hypoglycaemia in our IPT cohort (13.6 
events per 100 patient-years).  This difference in severe hypoglycaemia may explain why 
a significant decrease in A1C was observed in our IPT cohort, but not in that of Bode et 
al., despite similar glycaemic control at baseline. 
Paired Difference in Change in A1C 
In the matched analyses, a statistically significant paired difference in change in A1C 
from baseline to follow-up between the IPT and control subjects was not seen in 
Analysis 1. Possible reasons for why Analysis 1 did not show a significant difference are: 
there was, in fact, no true difference in the change in A1C between matched pairs of IPT 
and control subjects; the greater proportion of missing follow-up A1C values in the 
control cohort (47.1%) than in the IPT cohort (19.0%) masked the presence of a 
significant difference in the change in A1C; or the differences in baseline characteristics 
between those with vs. without missing follow-up A1C values influenced the ability to 
detect a significant paired difference in change in A1C. For example, IPT subjects with 
missing follow-up A1C values had lower BMI and lower TDD than those without missing 
values, while control subjects with missing follow-up A1C values had lower TDD and 
were less likely to have a private drug plan than those without missing values. As per the 
a priori power calculations (Table 3), the small sample size in Analysis 1 (n=74 pairs) was 
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less likely to be a reason for the lack of statistical significance (as even a sample size of 
n=50 per group would have been powered to detect a difference as small as 0.00027, or 
0.027%, between groups). 
However, a statistically significant mean paired difference in change in A1C between 
matched pairs of IPT and control subjects of -0.003 (or -0.3%) was seen in Analysis 2. The 
definition of a clinically meaningful change in A1C may be somewhat subjective, and to 
our knowledge, no studies have examined what constitutes a clinically meaningful 
difference in change in A1C (i.e. the clinically significant difference of a difference), but 
we believe that our observed paired difference in change in A1C is clinically significant. A 
2009 report by the Canadian Agency for Drugs and Technologies in Health90 noted that 
data on the minimally clinically important difference (MCID) in A1C for patients with 
T1DM is lacking, but prior studies91,92 comparing the effect of different types of insulin in 
lowering A1C in patients with T1DM have used a change in A1C of 0.3% as the MCID in 
power analyses. In addition, in their 2008 Guidance for Industry,93 the US Food and Drug 
Administration also defined a “clinically meaningful reduction” in A1C as 0.3%. 
Moreover, given that this mean paired difference in change in A1C of -0.3% between the 
IPT and control cohorts was seen in the context of fairly good baseline glycaemic control 
and was also accompanied by a decrease in the incidence of severe hypoglycaemia in 
the IPT cohort only further underscores the clinical significance of the results.  
The only previous observational study to report the difference in change in A1C from 
baseline to follow-up between matched IPT and control subjects was Carlsson et al.77 In 
their study, they found an unadjusted difference between groups for change in A1C 
from baseline to follow-up at 1 year of -0.00507, which is similar to (though slightly 
greater than) what we observed in our study. However, they also performed analysis of 
covariance adjusting for the baseline A1C, and the adjusted difference between groups 
at 1 year was -0.0042 (Table 14). We did not do an adjusted analysis in our study for the 
purpose of this thesis, but an adjusted analysis using multivariable regression to account 
for potential confounding factors is planned. 
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Proportion with Optimal A1C 
a) Comparison of Proportions at Baseline vs. at Follow-Up in each cohort 
Optimal glycaemic control is a key component in the management of T1DM. According 
to the 2013 CDA Clinical Practice Guidelines, the target A1C should be ≤ 0.070 for most 
patients with T1DM.2 However, it is also recommended that the target A1C level may be 
less strict (i.e. 0.071 - 0.085) in the presence of risk factors that make it unsafe to 
achieve tight glycaemic control (i.e. recurrent severe hypoglycaemia, hypoglycaemia 
unawareness, severe coronary artery disease, multiple comorbidities) or other situations 
in which the potential benefits of tight glycaemic control may not be outweighed by its 
risks (i.e. limited life expectancy, high level of functional dependency).2  
In our study, the proportion of subjects with an A1C of ≤ 0.070 increased from baseline 
to follow-up in the IPT cohort in both analyses (Analysis 1: from 27.0% to 33.3%, Analysis 
2: from 25.8% to 32.1%), but these increases were not statistically significant. In the 
control cohort, the proportion of subjects with an A1C of ≤ 0.070 increased from 
baseline to follow-up only in Analysis 1 (from 22.8% to 26.1%), but this was also not 
statistically significant. However, the proportions of IPT subjects with an A1C ≤ 0.073 or 
≤ 0.075 did significantly increase from baseline to follow-up (in both Analysis 1 and 2), 
yet this was not seen in control subjects. Taken together, this suggests that IPT may help 
improve glycaemic control to a certain level, but that there may be a threshold below 
which it is difficult to further improve glycaemic control—for example, due to limitations 
from hypoglycaemia. Once a patient has reached target optimal glycaemic control (i.e. ≤ 
0.070) it may be difficult to further lower the A1C, regardless of the method of insulin 
delivery. This likely reflects the larger problem of failure to recreate true physiological 
insulin delivery in patients with longstanding T1DM. 
Mecklenburg et al.61 examined the proportions of subjects with a “normal” A1C at 
baseline and while on IPT. In contrast to our study, the proportion of subjects that 
achieved a target (i.e. normal) A1C was statistically significantly higher during the first 
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year on IPT (26%, n=33) than that at baseline (9%, n=11) (p=0.0001). However, in 
Mecklenburg et al.,61 the A1C was “…calculated as a percentage of the mean in a normal 
population and converted to the comparable absolute values in our present assay….” 
and the normal range of their assay was 0.0045 - 0.0080 (4.5-8.0%).  Thus, the threshold 
for their target A1C was higher than what was defined as “optimal” in our study.  
Furthermore, 8 of the 33 subjects in their study who achieved the target A1C during the 
first year on IPT were pregnant, while pregnancy was an exclusion in our study.  
Reda et al.69 also compared the proportions of subjects achieving an A1C ≤ 0.070 pre- 
and post-IPT start in their study of 105 subjects. In contrast to our study, they found that 
a higher proportion of subjects achieved an A1C ≤ 0.070 after IPT start (17.1%, n=18) 
compared to before the IPT start (8.6%, n=9). However, they followed subjects up to 6 
years after initiation of IPT, but did not specify at what time point after IPT start the 
subjects achieved the target A1C. Similarly, Sudhakaran et al.72 showed an increase in 
the proportion of subjects achieving an A1C <0.070 on IPT compared to pre-IPT (from 0% 
to 17.6%). However, their number of subjects with T1DM was small (n=17). Marmolin et 
al.75 also showed an increase in the proportion of subjects who attained an A1C ≤ 0.070 
on IPT compared to pre-IPT, from 13% (n=8) to 24% (n=14). In none of these 3 studies 
was it stated whether the increase in proportion of IPT users achieving their target A1C 
was statistically significant.69,72,75 
b) Comparison of Proportions at Follow-Up between IPT vs. Control Cohorts 
Since both the IPT and control cohorts had comparable glycaemic control at baseline, 
the proportion of subjects who achieved an optimal A1C value at follow-up was 
compared between the IPT and control cohorts.  In both Analysis 1 and 2, there was a 
higher proportion of subjects with an A1C ≤ 0.070 at follow-up in the IPT cohort than in 
the control cohort, though only Analysis 2 showed that this difference was statistically 
significant. The differing results between Analysis 1 and 2 may again be a function of 
sample size, as Analysis 1 included only 74 pairs, while Analysis 2 included almost double 
the sample size. (Other potential reasons for the differing results are as stated 
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previously above). No prior study compared this proportion at follow-up between an IPT 
and control cohort.  
5.2.4 Adverse Events  
In our study, there were no episodes of DKA at baseline or at follow-up in either cohort. 
This is similar to 2 prior retrospective cohort studies, where the incidence of DKA was 
negligible in subjects pre- or post-IPT start. 67,72 Several other studies did observe 
episodes of DKA but did not note any significant change in the incidence of DKA before 
or after IPT use.63,70 Reda et al. reported an incidence of 20 episodes per 100 patient-
years in the year prior to IPT start and an incidence of 5 episodes per 100 patient-years 
during IPT use, but it was not stated whether this was a statistically significant 
decrease.69  
In our study, there was no significant difference in the baseline incidence of severe 
hypoglycaemia between cohorts, but after 1 year post-IPT/t=0, the IPT cohort had a 
significantly lower incidence of severe hypoglycaemia compared to the control cohort. 
Other studies have also shown a decrease in the incidence of severe hypoglycaemia with 
the initiation of IPT use.63,65,67,69-72 Bode et al. reported a decrease in incidence from 138 
events per 100 patient-years while on MDI to 22 events per 100 patient-years while on 
IPT63. However, this study was conducted specifically in subjects with recurrent severe 
hypoglycaemia, which is why the baseline incidence was so high.  Similarly, the other 
studies65,67,69-72,75 which showed a significant decrease in incidence of severe 
hypoglycaemia with IPT use all had higher incidences at baseline than our study—we 
observed an incidence of only 13.6 events per 100 patient-years (IPT cohort) and 13.0 
events per 100 patient-years (control cohort) at baseline. This compares to the other 6 
studies that had baseline incidences of severe hypoglycaemia at least 2-fold greater than 
ours. The low baseline incidence of severe hypoglycaemia seen in our subjects is likely 
related to the amount of missing adverse event data in both cohorts. In turn, this likely 
contributed to our limited ability to detect any differences from baseline to follow-up 
within each cohort, and between cohorts.  
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5.2.5 Subgroup Analysis 
In our study, subgroup analysis showed that IPT subjects with a baseline A1C ≥ 0.081 had 
a mean change in A1C of -0.007 from baseline to follow-up, while IPT subjects with a 
baseline A1C 0.071 to 0.080 showed no change, and those with a baseline A1C ≤ 0.070 
had a mean 0.004 increase in A1C from baseline to follow-up. In the control cohort, 
subjects with a baseline A1C ≤ 0.070 also had an increase in A1C from baseline to follow-
up (mean 0.003 to 0.004 increase), but no significant change in A1C was seen in the 
control subjects with a baseline A1C 0.071 to 0.080 or ≥ 0.081. Of note, severe 
hypoglycaemia was not the reason for why the subgroup with baseline A1C ≤ 0.070 in 
both cohorts showed a significant increase in A1C from baseline to follow-up. In fact, the 
majority of severe hypoglycaemic episodes at baseline were seen in the subgroup with 
baseline A1C ≥ 0.081 in both cohorts—82.3% (n=14) in the IPT cohort and 66.7% (n=10) 
in the control cohort. However, even though the highest baseline severe hypoglycaemia 
incidence was in the subgroup with baseline A1C ≥ 0.081 in both cohorts, this subgroup 
in the IPT cohort was still able to show a significant reduction in A1C at follow-up, yet 
this subgroup in the control cohort was not. 
Our results are similar to other studies which showed a differential effect of IPT use on 
glycaemic control depending on baseline A1C.63,67,71 Bode et al.63 demonstrated that 
those with a baseline A1C ≥ 0.080 had a significant decrease in A1C with IPT use, 
whereas those with a baseline A1C < 0.080 did not have any change in A1C with IPT use. 
Lepore et al.67 found that those subjects with a baseline A1C > 0.100 had a greater A1C 
reduction (-0.015 ± 0.006) with IPT use vs. those with a baseline A1C < 0.080 (-0.006 ± 
0.005). Riveline et al.71 also showed a significant (-0.090) improvement in A1C in subjects 
with a baseline A1C ≥ 0.090. However, Giménez et al.70 did not find any difference in 
glycaemic control in subgroups of subjects divided by baseline A1C ≤ 0.070 or > 0.070, 
though given that the mean baseline A1C in their study was 0.079 ± 0.013, the subgroup 
with baseline A1C > 0.070 likely had too few numbers to show a difference in subgroup 
analysis. 
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5.3 Use of WebDR as a Researchable Database 
WebDR was a convenient tool which was used to: a) identify all patients with T1DM 
followed by the Diabetes Clinics at SJHC, b) assemble a cohort of IPT users and c) 
construct a cohort of non-IPT users from which we could select matched controls. This 
was the first use of WebDR for research, and the process allowed us to identify both its 
strengths and weaknesses as a researchable database. 
5.3.1 Identification of Insulin Pump Therapy Cohort and Matched Controls 
There are no data fields in WebDR to specifically identify ADP-funded adult IPT users. 
Instead, adults with T1DM on IPT were identified via a WebDR query of medication lists 
for insulin pump-compatible insulins and insulin doses, and review of their physician 
paper chart was performed to confirm ADP coverage. However, to ensure that all 
eligible IPT users followed by the Diabetes Clinics at SJHC were identified, IPT use was 
also independently verified by comparison to the list of adults started on IPT maintained 
by the St. Joseph’s Hospital DEC. Comparing those IPT users identified by WebDR to 
those identified by the DEC list showed a 46% concordance between the two data 
sources (i.e. of the 229 IPT users identified by WebDR, only 105 were also identified by 
the DEC list, while the other 124 were not identified by the DEC list). An additional 119 
IPT users on the DEC list were not identified by WebDR.  Possible reasons for why 
patients were listed as IPT users on WebDR but not on the DEC list are: IPT use was 
initiated at another DEC (instead of the St. Joseph’s Hospital DEC); IPT was started when 
the patient was under the care of the pediatric program; the patient was on IPT but not 
funded by the ADP; or IPT was started prior to September 2008 or after August 2011 and 
the IPT start date was not documented on WebDR.  Possible reasons for why patients 
were listed as IPT users on the DEC list but not on WebDR are: IPT doses were not 
entered in the patient’s WebDR record; IPT was started during pregnancy (the Endocrine 
Pregnancy Clinic is the only clinic at SJHC that sees adult patients with T1DM but that 
does not use WebDR); or the patient was no longer followed by a physician at the 
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Diabetes Clinics at SJHC and so they were not entered into WebDR or their WebDR 
record was inactivated. 
In our study, use of both WebDR and the DEC list allowed us to be confident that all 
eligible adults with T1DM on IPT followed by the Diabetes Clinics at SJHC were 
identified. However, it does highlight that the use of WebDR as the sole data source to 
identify patients who started IPT between September 2008 and August 2011 would not 
have captured all IPT users at SJHC during that time. Of note, at the time of manual data 
entry of clinical data from physician paper charts (in 2010-2011), documentation of IPT 
use was not the highest priority.  However, WebDR has now been in routine clinical use 
for over 2 years with ongoing updates of patient records at each clinic visit (including 
medication lists). We expect that the accuracy of WebDR in identifying IPT users will 
have improved, and thus may be used in future studies involving patients on IPT. To 
confirm this, a paper chart review of all adult patients with T1DM followed by the 
Diabetes Clinics at SJHC is planned, with cross-reference to WebDR to ensure electronic 
documentation of IPT use and ADP coverage. 
5.3.2 Validation of A1C Dates and Values 
Validation of the baseline and follow-up A1C levels and dates was performed. It showed 
that WebDR had fair to good (69.4% to 80.6%) accuracy for these variables. Of note, 
there were no instances where the WebDR value was incorrect compared to the 
reference standard, but rather, the inaccuracy observed was due to missing values in 
WebDR. This is related to our study data collection period and the protocol for manual 
data entry for data from physician paper charts that was performed in 2010-2011. Given 
that the ADP started in September 2008, we required A1C values as early as March 
2007. However, when manual data entry was performed, for most physician charts, only 
the most recent A1C few values would be entered (and the number of values could 
range depending on the data entry clerk).   
The accuracy of historical A1C data of our study cohort should now be improved 
compared to when our validation was performed, since missing data was entered into 
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WebDR at the time of data extraction.  As well, WebDR data from 2011 onwards will 
likely also be more accurate than what we observed in our validation, given that WebDR 
is now being used routinely for clinic visits at almost all of the Diabetes Clinics at SJHC. 
The use of WebDR in this study allowed us the opportunity to assess the accuracy of the 
glycaemic control data within WebDR, and will help improve its accuracy for use in 
future research studies.  
 
5.4 Study Strengths  
This study is one of only a few observational cohort studies that has evaluated the effect 
of IPT on glycaemic control in a large cohort of adults with T1DM on IPT as compared to 
a control cohort of adults with T1DM not on IPT in a “real-world” setting.  
In addition, this study is the largest descriptive cohort of adults with T1DM on IPT in 
Canada to date. It is also the only study to describe a population of IPT users who are 
funded by the Ontario MOHLTC ADP, which has provided IPT funding for adults with 
T1DM for the past 5 years. The subjects in our study were all followed by the Diabetes 
Clinics of SJHC, a major tertiary care centre with a large geographic catchment area in 
Southwestern Ontario, and thus they are likely representative of adults with T1DM both 
provincially and nationwide. We judge that our cohort can be used in future studies 
evaluating the impact of ADP-funded IPT on adults with T1DM in Ontario. This should 
provide valuable information to health policy makers in at least Ontario, if not across 
Canada, where funding programs for adults using IPT are varied, or may not exist at all.  
Another strength is in the design and analysis of our study. We used 1:1 matching in the 
selection of our control cohort and purposefully chose change in A1C as our primary 
outcome in an attempt to control for bias due to confounding by 3 important factors: 
baseline A1C, age, and duration of T1DM. Prior observational studies67,68,71, 94,95 and 
meta-analyses of before-after studies and/or RCTs5,6 have shown that the baseline A1C 
is one of the most (if not the most) important factor predictive of improved glycaemic 
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control on IPT. Other observational studies have also found that age 67,94-96 and duration 
of T1DM95 are related to glycaemic control on IPT.  
 
5.5 Study Limitations  
Our study had several limitations. As a retrospective observational study, it was limited 
to the data available on WebDR and in the physician paper charts. This reduced our 
ability to control for known confounding factors. Despite ensuring that the cohorts were 
well-matched for age and duration of T1DM, it is possible that other differences 
between the IPT and control cohorts may have contributed to the results seen. We also 
attempted to control for differences in baseline A1C by selecting the change in A1C as 
our primary outcome, but other potentially important factors exist that could confound 
the association between IPT use and glycaemic control.   
For example, the greater decrease in A1C seen in the IPT cohort compared to the control 
cohort could be due not to IPT per se, but rather to the intensive training and education 
that is required prior to initiation of IPT. Further, the patients who are willing to go on 
IPT may be inherently more motivated to manage their T1DM in comparison to those 
who do not. However, our study does reflect “real-world” conditions in which there are 
patients with a wide range of ability for self-management of their T1DM, and in which 
some choose to pursue IPT and others do not.  
Other factors shown to have been associated with improved glycaemic control on IPT 
include blood glucose variability while on an MDI regimen68,76 and the use of a bolus 
dose calculator for at least 50% of boluses.97 As data on these factors were not collected 
routinely in WebDR or in physician paper charts, we were not able to include these 
variables in our study.  
Confounding by indication may also be a limitation in our study, as we did not collect 
information on the indication for IPT use. It is possible that those patients who were 
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started on IPT were recommended to do so by their physicians if their glycaemic control 
was persistently suboptimal on MDI, as compared to those patients who were 
maintained on MDI, and subsequently be more motivated to improve their glycaemic 
control. However, it is somewhat reassuring that the mean A1C in the IPT and control 
cohorts was similar at baseline, which would not be expected if the main indication for 
IPT in our IPT cohort was suboptimal glycaemic control.  
We did measure other clinical variables at baseline that have been shown to be 
associated with glycaemic control in adults with T1DM (higher income or educational 
status98 and frequency of CBG monitoring99) and in those with T1DM specifically on an 
MDI regimen (BMI and insulin dose)68 or on IPT (frequency of CBG monitoring71 and 
presence of complications).95 There was no difference in average household income, 
mean BMI, or mean TDD at baseline between the cohorts. The IPT cohort did perform 
more CBG monitoring at baseline, which may have contributed to the difference in 
glycaemic control seen between the IPT and control cohorts. However, the IPT cohort 
had a smaller proportion of subjects with at least 1 glycaemic-responsive complication 
(i.e. neuropathy), and a prior study95 found that the presence of complications was 
predictive of better glycaemic control on IPT. We did not yet perform an analysis 
adjusting for these factors; however, this is planned. 
Another limitation of our study was the amount of missing outcome data (follow-up A1C 
and adverse events) in both cohorts. To address this, 2 analyses were performed for our 
primary outcome—Analysis 1 (no imputation) and Analysis 2 (imputation using LOCF for 
the missing follow-up A1C values). The proportion of missing values between the IPT and 
control cohorts differed significantly in Analysis 1, but there was no significant difference 
between cohorts in Analysis 2. Differences in the proportion of missing follow-up A1C 
values may explain why Analysis 1 did not show a statistically significant difference in 
the paired difference in A1C change score, while Analysis 2 did show a statistically 
significant difference. 
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Of note, an important assumption for use of LOCF in our study was that the follow-up, 
but missing, A1C did not significantly change from the last available A1C level. In Analysis 
2, 18/174 (10.3%) of IPT subjects and 55/174 (31.6%) of control subjects had their 
follow-up A1C imputed. However, of these imputed values, a large proportion of them, 
in both cohorts (14/18, 77.8% in IPT cohort; 24/55, 43.6% in control cohort) were carried 
forward from measurements taken between 8-10 months post IPT start/t=0 (i.e. 
relatively close to the pre-specified window for follow-up A1C). We think it improbable 
that the A1C changed significantly from 8-10 months until 10.5 months. Furthermore, a 
prior study by Cohen et al.78 showed that the greatest A1C reduction while on IPT 
occurred in the first 6 months, with significant decreases in A1C persisting up until 3 
years. Similarly, Lepore et al.67 showed a significant A1C reduction in patients on IPT 
within 3 months that persisted until 2 years.  Together, this supports our use of LOCF to 
impute follow-up A1C values prior to 1 year in our study.   
Another limitation in our study is selection bias and its effect on the generalizability of 
our results. Since we excluded adults with < 1 year duration of T1DM, IPT patients with < 
1 year of IPT use, and pregnant women, our results may not be generalizable to these 
populations.  
Another potential source of selection bias was the exclusion of patients who did not 
have a post-IPT start/t=0 follow-up A1C documented, and those no longer followed (i.e. 
with an inactive WebDR record), because they did not return to the Diabetes Clinics for 
follow-up. These patients may represent a less motivated population whose glycaemic 
control may have worsened during follow-up. In our study, only 1 IPT patient did not 
have a follow-up A1C. This is not unexpected, as at least 2 A1C measurements per year 
are required for renewal of ADP funding so this ensures that patients return for follow-
up to the Diabetes Clinics. However, 10 control patients with baseline A1C values 
available were not selected due to not having a follow-up A1C (either not documented 
in WebDR/physician paper chart, or else were no longer followed/inactive record), so 
given the higher number of control patients excluded for this reason, there is a concern 
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that the control subjects in our study are a selected sample of more motivated patients. 
However, if this was the case, it would bias the results toward the null, as the difference 
in A1C change score between the IPT and control cohorts would be smaller. However, 
given that we did observe a significant difference (in Analysis 2), then it may be inferred 
that, had it been possible to include those control subjects excluded for no follow-up 
A1C, the difference in A1C change score would have been even larger than what was 
observed.  
 
5.6 Future Directions 
The results of this study provide evidence to support a beneficial effect of IPT use in 
improving glycaemic control in adults with T1DM. We used matching in the design and 
analysis to help limit bias due to confounding by age and duration of T1DM, and selected 
the change in A1C as our primary outcome to take baseline A1C into account. However, 
this study did not use multivariable analysis to adjust for other potential confounding 
variables, such as the differences in baseline characteristics seen between the control 
and IPT cohorts. Therefore, the next step will be to perform multiple linear regression 
analyses to adjust for these baseline differences between the cohorts to obtain a 
potentially less-confounded estimate of the association between IPT and glycaemic 
control in adults with T1DM.   
This study was the first to characterize patients on IPT who are funded by the Ontario 
MOHLTC ADP. Future planned studies building on these results include a validation study 
with our IPT cohort to validate the Ontario-wide data of all adults on ADP-funded IPT, 
and a health care utilization study. We plan to link our cohort data to provincial 
healthcare administrative databases to examine the effect of IPT use on important 
diabetes-related health care utilization outcomes (i.e. physician outpatient visits, eye 
examinations, diabetes-related emergency room visits and hospitalizations).  
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Data from our IPT cohort may also be used in a future cost-effectiveness analysis of IPT 
therapy in Ontario. A prior health economic comparison study100 in 2009 showed that 
IPT may be cost-effective as compared to MDI in adults with T1DM in Canada, but the 
study used a theoretical sample with demographic and clinical characteristics based on 
those from subjects in the DCCT.26 However, it would be interesting to determine 
whether similar results would be obtained if the analysis was done using data from our 
real-world IPT cohort. 
Lastly, this study was the first to use WebDR, the EMR system of the Diabetes Clinics at 
SJHC, for clinical research, and this was the first step in establishing its utility as a 
comprehensive researchable database for use in the future to examine other important 
clinical research questions in patients with diabetes.   
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5.7 Conclusions 
Prior meta-analyses of RCTs have shown that IPT can cause a small but significant 
improvement in glycaemic control as compared to an MDI regimen. However, there is 
more limited evidence for the benefits of IPT in improving glycaemic control and adverse 
events under “real-world” conditions, and no studies have been performed in Canada.  
Ontario was the first province in Canada to implement a government funding program 
supporting the use of IPT in adults, and the program has been in place for 5 years. This 
study is the first to characterize a population of ADP-funded IPT users, and to assess the 
clinical impact of this funding program in adults. Our findings suggest that ADP-funded 
IPT is associated with a clinically relevant improvement in glycaemic control and a 
significant decrease in severe hypoglycaemia in adults with T1DM as compared to a 
matched control population. This is consistent with findings from prior RCTs, and 
provides “real-world” evidence in support of the clinical benefits afforded by the 
MOHLTC ADP funding for IPT in Ontario. The results of this study should help inform 
health policy makers in Ontario, and encourage continued government support of IPT in 
adults with T1DM. 
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Appendix A – Summary of Existing Funding Programs for Insulin Pump Therapy in Canada 
ONTARIO 
Pediatric program: 
≤ 18 yrs 
Adult program: 
≥ 19 yrs 
BRITISH COLUMBIA 
Children ≤ 18 yrs 
ALBERTA 
All ages 
 
YUKON, NORTHWEST TERRITORIES, 
NUNAVUT  
(considered on individual basis under 
Non-Insured Health Benefits Plan) 
 
SASKATCHEWAN 
Youth ≤ 25 yrs 
(pump & supplies age ≤ 17 
pump only age 18-25) 
NEWFOUNDLAND & 
LABRADOR 
Youth ≤ 25 yrs 
MANITOBA 
Children < 18 yrs 
QUEBEC 
Children ≤ 18 yrs 
* Prince Edward Island has no current coverage 
NOVA SCOTIA 
Youth ≤ 24 yrs 
(pump & supplies age ≤ 18 
pump only age 19-24)  
NEW 
BRUNSWICK 
Children ≤ 18 yrs 
* 
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London 
Owen Sound, Stratford, St. Thomas, Woodstock 
 Appendix B – Adult Assistive Devices Program Insulin Pump Therapy Clinics in 
the Ontario South West Local Health Integration Network 
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Initial Application 
1. Applicant has Type 1 diabetes 
2. Applicant has demonstrated experience with a basal/bolus insulin regimen for at 
least one year 
3. Applicant demonstrates the ability to self-assess and take action based on blood 
glucose results by: carbohydrate counting, correction bolus & sick day 
management 
4. Applicant demonstrates a commitment to long-term diabetes follow-up through 
regular assessments by diabetes educators and physicians at least 3 times a year 
or as deemed appropriate by the diabetes team 
5. Applicant has participated in a pre-assessment for insulin pump therapy 
according to ADP requirements 
Yearly Renewal 
1. Applicant continues to demonstrate an ongoing commitment to blood glucose 
monitoring a minimum of four times daily 
2. Applicant demonstrates the ability to self-assess and take action based on blood 
glucose results by: carbohydrate counting, correction bolus & sick day 
management 
3. Applicant has demonstrated that they have benefited from pump therapy 
through one of the following results: 
a. Improved quality of life 
b. Improved A1C results 
c. Reduction in the number of hypoglycaemic events 
d. Reduction in the number of diabetic ketoacidosis episodes  
e. Improved management of the “dawn phenomenon” 
4. Applicant demonstrates a commitment to long-term diabetes follow-up through 
regular assessments by diabetes educators and physicians at intervals deemed 
appropriate by the ADP Registered Adult Diabetes Program 
 
 
 
 
Appendix C – Assistive Devices Program – Adult Eligibility Criteria for Initial 
Application and for Yearly Renewal 
  
 
 
 
Appendix D – Assistive Devices Program – Adult Application Form  
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Appendix E – Assistive Devices Program – Adult Renewal Form 
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Appendix G – Western University Health Sciences Research Ethics Board Revision 
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The accuracy of WebDR was assessed as compared to the physician paper chart, which 
was used as the reference standard for comparison. A computer-generated random 
sample of 36 patient records (i.e. 10% of the total sample size) was selected for the 
validation. Four variables were validated for accuracy: baseline (i.e. pre-IPT start/t=0) 
A1C value, baseline A1C date, follow-up (i.e. post-IPT start/t=0) A1C value, and follow-up 
A1C date. If the WebDR value matched the physician paper chart value, it was coded as 
a “match”, but if the WebDR value and the physician paper chart value did not match, it 
was coded as “no match”. If there was no WebDR value recorded but a value was 
present in the physician paper chart, it was coded as “not recorded”. 
The results of the validation are presented below: 
 
Variable Match (%) No Match (%) Not Recorded (%) 
Baseline A1C value 25 (69.4%) 0 (0%) 11 (30.6%) 
Baseline A1C date 25 (69.4%) 0 (0%) 11 (30.6%) 
Follow-Up A1C value 29 (80.6%) 0 (0%) 7 (19.4%) 
Follow-Up A1C date 28 (77.8%) 0 (0%) 8 (22.2%) 
 
Therefore, the accuracy of WebDR for the baseline and follow-up A1C levels and dates in 
our study could be considered fair to good, with accuracy ranging from 69.4% - 80.6%. 
The inaccuracy present was due to missing values in WebDR, as opposed to incorrect 
values in WebDR. 
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Appendix J – Baseline Characteristics of those with Missing vs. Non-Missing Follow-Up A1C Values – Insulin Pump Therapy Cohort 
 
*
Optimal defined as ≤ 0.070; 
§
glycaemic-responsive complications defined as retinopathy, nephropathy, neuropathy 
IPT, insulin pump therapy; A1C, glycated hemoglobin; T1DM, type 1 diabetes mellitus; CVD, cerebrovascular disease; CAD, coronary artery disease; PVD, peripheral 
vascular disease; BMI, body mass index; kg, kilogram, m, meter; TDD, total daily insulin dose; CBG, capillary blood glucose 
Comparisons between missing and non-missing groups using 
†
two sample t-test, 
‡
Chi-square test, or 
**
Fisher’s Exact test 
 Analysis 1 Analysis 2 
  
IPT Non-Missing 
                                       n 
 
IPT Missing 
                                       n 
 
p-value  
 
IPT Non-Missing 
                                        n  
 
IPT Missing 
                                          n 
 
p-value  
Age (years)  45.4 ± 12.3 
 
141 
 
43.3 ± 14.7 
 
33 
 
0.465
†
 45.4 ± 12.8 
159 
41.0 ± 11.9 
15 
0.194
†
 
Duration of T1DM (years)  25.2 ± 12.8 25.2 ± 14.8 0.984
†
 25.2 ± 13.2 25.0 ± 12.9 0.952
†
 
Gender (Male) – n (%) 62 (44.0) 18 (54.6) 0.273
‡
 74 (46.5) 6 (40.0) 0.627
‡
 
Private Drug Plan - n (%) 9 (6.4) 3 (9.1) 0.701
**
 10 (6.3) 2 (13.3) 0.276
**
 
City (London) - n (%) 63 (44.7) 17 (51.5) 0.478
‡
 72(45.3) 8 (53.3) 0.550
‡
 
Physician (Endocrinologist) – n (%) 137 (97.2) 32 (97.0) 1.000
**
 155 (97.5) 14 (93.3) 0.366
**
 
Average Yearly Household Income  $70,976 ± $12,897 $70,695 ± $12,845 0.911
†
 $70,869 ± $12,662 $71,491 ± $15,191 0.880
†
 
Baseline A1C 0.077 ± 0.010 0.079 ±0.013 0.562
†
 0.078 ± 0.011 0.077 ± 0.010 0.693
†
 
Optimal
*
 baseline A1C – n (%) 38 (27.0) 6 (18.2) 0.297
‡
 41 (25.8) 3 (20.0) 0.763
**
 
Current smoking – n (%) 7 (5.0) 0 (0.0) 0.349
**
 7 (4.4) 0 (0.0) 1.000
**
 
At least 1 complication – n (%) 49 (34.8) 11 (33.3) 0.877
‡
 55 (34.6) 5 (33.3) 0.992
‡
 
At least 1 glycaemic-responsive
§ 
complication – n (%) 
48 (34.0) 10 (30.3) 0.682
‡
 53 (33.3) 5 (33.3) 1.000
‡
 
Complications – n (%)                CVD 
CAD 
PVD 
Retinopathy 
Nephropathy 
Neuropathy 
0 (0) 0 (0) N/A 0 (0.0) 0 (0.0) N/A 
4 (2.8) 2 (6.1) 0.319
**
 5 (3.1) 1 (6.7) 0.423
**
 
1 (0.7) 0 (0) 1.000
**
 1 (0.6) 0 (0.0) 1.000
**
 
30 (21.3) 9 (27.3) 0.457
‡
 34 (21.4) 5 (33.3) 0.331
**
 
18 (12.8) 7 (21.2) 0.268
**
 22 (13.8) 3 (20.0) 0.456
**
 
16 (11.4) 3 (9.1) 1.000
**
 18 (11.3) 1 (6.7) 1.000
**
 
Baseline BMI (kg/m
2
) 26.8 ± 4.9 126 25.2 ± 3.6 30 0.049
†
 26.5 ± 4.7 142 25.9 ± 4.6 14 0.664
†
 
Baseline TDD (units) 54.1 ± 26.6 131 43.8 ± 18.4 30 0.014
†
 53.0 ± 26.0 147 43.6 ± 19.4 14 0.110
†
 
Baseline # CBG/day 4.0 ± 0.7 130 4.1 ± 0.9 33 0.797
†
 4.0 ± 0.8 148 4.0 ± 0.8 15 0.907
†
 
Baseline # injections/day        4.2 ± 0.5 135 4.2 ± 0.6 33 0.538
†
 4.2 ± 0.6 153 4.1 ± 0.4 15 0.585
†
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Appendix K – Baseline Characteristics of those with Missing vs. Non-Missing Follow-Up A1C Values – Control Cohort 
 
*
Optimal defined as ≤ 0.070, 
§
glycaemic-responsive complications defined as retinopathy, nephropathy, neuropathy 
A1C, glycated hemoglobin; T1DM, type 1 diabetes mellitus; CVD, cerebrovascular disease; CAD, coronary artery disease; PVD, peripheral vascular disease; BMI, body 
mass index; kg, kilogram, m, meter; TDD, total daily insulin dose; CBG, capillary blood glucose 
Comparisons between missing and non-missing groups using 
†
two sample t-test, 
‡
Chi-square test, or 
**
Fisher’s Exact test 
 Analysis 1 Analysis 2 
  
Control Non-Missing 
                                         n 
 
Control Missing 
                                        n 
 
p-value  
 
Control Non-Missing 
                                          n  
 
Control Missing 
                                           n 
 
p-value  
Age (years)  45.7 ± 14.0 
 
92 
 
44.9 ± 12.3 
 
82 
 
0.675
†
 45.4 ± 13.5 
148 
44.6 ± 11.8 
26 
0.748
†
 
Duration of T1DM (years)  26.8 ± 12.9 23.4 ± 13.3 0.092
†
 25.4 ± 13.1 24.2 ± 13.4 0.693
†
 
Gender (Male) – n (%) 52 (56.5) 45 (54.9) 0.828
‡
 84 (56.8) 13 (50.0) 0.522
‡
 
Private Drug Plan - n (%) 21 (22.8) 9 (11.0) 0.039
‡
 26 (17.6) 4 (15.4) 1.000
**
 
City (London) - n (%) 47 (51.1) 43 (52.4) 0.859
‡
 77 (52.0) 13 (50.0) 0.849
‡
 
Physician (Endocrinologist) – n (%) 85 (92.4) 74 (90.2) 0.614
‡
 136 (91.9) 23 (88.5) 0.473
**
 
Average Yearly Household Income  $71,909 ± $13,993 $68,979 ± $13,806 0.167
†
 $70,396 ± $13,892 $71,285 ± $14,480 0.773
†
 
Baseline A1C 0.078 ± 0.013 0.078 ± 0.012 0.933
†
 0.079 ± 0.013 0.075 ± 0.010 0.078
†
 
Optimal
*
 baseline A1C – n (%) 21 (22.8) 22 (26.8) 0.541
‡
 34 (23.0) 9 (34.6) 0.204
‡
 
Current smoking – n (%) 15 (16.3) 18 (22.0) 0.343
‡
 26 (17.6) 7 (26.9) 0.281
**
 
At least 1 complication – n (%) 45 (48.9) 33 (40.2) 0.251
‡
 69 (46.6) 9 (34.6) 0.256
‡
 
At least 1 glycaemic-responsive
§ 
complication – n (%) 
43 (46.7) 33 (40.2) 0.389
‡
 67 (45.3) 9 (34.6) 0.312
‡
 
Complications – n (%)               CVD 
CAD 
PVD 
Retinopathy 
Nephropathy 
Neuropathy 
1 (1.1) 1 (1.2) 1.000
**
 2 (1.4) 0 (0) 1.000
**
 
4 (4.4) 2 (2.4) 0.685
**
 6 (4.1) 0 (0) 0.593
**
 
0 (0) 0 (0) N/A 0 (0) 0 (0) N/A 
29 (31.5) 22 (26.8) 0.497
‡
 47 (31.8) 4 (15.4) 0.091
‡
 
18 (19.6) 19 (23.2) 0.562
‡
 33 (22.3) 4 (15.4) 0.427
‡
 
18 (19.6) 15 (18.3) 0.831
‡
 27 (18.2) 6 (23.1) 0.590
**
 
Baseline BMI (kg/m
2
) 27.4 ± 5.4 79 27.0 ± 5.6 70 0.660
†
 27.1 ± 5.3 126 28.1 ± 6.2 23 0.453
†
 
Baseline TDD (units) 62.9 ± 39.4 89 52.8 ± 25.4 81 0.048
†
 59.2 ± 35.5 144 51.8 ± 20.6 26 0.147
†
 
Baseline # CBG/day 3.6 ± 0.9 84 3.9 ± 0.8 74 0.089
†
 3.7 ± 0.9 136 3.7 ± 0.6 22 0.712
†
 
Baseline # injections/day        4.2 ± 0.6 88 4.2 ± 0.8 80 0.859
†
 4.2 ± 0.7 142 4.2 ± 0.9 26 0.702
†
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